

CURRICULUM VITAE

ALLEN J. DOZOR

ADDRESS: Home: 1385 York Avenue
Apartment 8F
New York, NY 10021

Office: Pediatric Pulmonology, Allergy, Immunology, and Sleep Medicine
Boston Children's Health Physicians
New York Medical College
40 Sunshine Cottage Road - Skyline 1N-D30
Valhalla, NY 10595

EDUCATION:

1973 B.A., University of Pennsylvania
1977 M.D., Pennsylvania State University
Milton S. Hershey Medical Center, Hershey, Pennsylvania

POSTGRADUATE TRAINING:

Internship and Residencies:

1977- 1978 Resident in Pediatrics, St. Vincent's Hospital and Medical Center of New York, New York, New York
1978- 1979 Senior Resident in Pediatrics, St. Vincent's Hospital and Medical Center of New York, New York, New York
1979- 1980 Chief Resident in Pediatrics, St. Vincent's Hospital and Medical Center of New York, New York, New York

Research and Clinical Fellowship:

1980- 1982 Fellow in Pulmonary Medicine, Children's Hospital Medical Center and Harvard Medical School, Boston, Massachusetts

ACADEMIC FACULTY APPOINTMENTS:

1980 Fellow in Pediatrics, Harvard Medical School, Boston, Massachusetts
1982 Instructor in Pediatrics, Harvard Medical School, Boston, Massachusetts
1983 Assistant Professor of Pediatrics, New York Medical College, Valhalla, New York
1985 Chief, Pediatric Pulmonology, New York Medical College, Valhalla, New York
1996 Associate Professor of Pediatrics, New York Medical College, Valhalla, New York
2002 Professor of Pediatrics, New York Medical College, Valhalla, New York
2009 Professor of Clinical Public Health, New York Medical College, Valhalla, New York

HOSPITAL, MEDICAL COLLEGE AND PRACTICE ADMINISTRATIVE APPOINTMENTS:

1982 Assistant in Medicine, Attending in Pediatric Pulmonology and Pediatric Intensive Care, Children's Hospital Medical Center, Boston, Massachusetts
1983 – 1985 Attending Physician, Director of Diagnostic, Exercise, and Research Laboratories, Pulmonary Division, Department of Pediatrics, St. Vincent's Hospital and Medical Center of New York, New York
1985 - Present Chief, Section of Pediatric Pulmonology, Westchester Medical Center, Valhalla, New York
1985 - 1996 Consultant in Pediatric Pulmonology, Nyack Hospital, Nyack, New York
1985 - 1995 Director, Regional Infant Apnea Center, Westchester Medical Center, Valhalla, New York
1986 - Present Medical Director, Pediatric Respiratory Care, Westchester Medical Center, Valhalla, New York
1989 - Present Director, Armond V. Mascia, M.D. Cystic Fibrosis Center, Westchester Medical Center, Valhalla,

New York

1991 - 1995 Director, Pediatric Intensive Care Unit, Westchester Medical Center, Valhalla, New York

1992 - 1998 Attending, Department of Pediatrics, Pediatric Pulmonology, St. Agnes Hospital, White Plains, New York

1992 - Present Associate Director of Pediatrics, Westchester Medical Center, Valhalla, New York

1992 - Present Director, Fellowship in Pediatric Pulmonology, Westchester Medical Center and New York Medical College, Valhalla, New York

1995 - Present Member of the Executive Committee of Children's and Women's Physicians of Westchester LLP (The Faculty Practice of the Departments of Pediatrics of New York Medical College)

1997 - Present Managing Partner, Managing Partner, Children's and Women's Physicians of Westchester, LLP (The faculty practice organization of the Department of Pediatrics, New York Medical College, Valhalla, New York Medical College)

1999 - Present Director, American Lung Association Asthma Clinical Research Center, Westchester Medical Center and New York Medical College, Valhalla, New York

2002 - Present Chief, Combined Sections of Pediatric Pulmonology, Allergy and Sleep Medicine, Children's and Women's Physicians of Westchester, LLP, Valhalla, New York

2003- Present Associate Physician-In-Chief, Maria Fareri Children's Hospital at Westchester Medical Center, Valhalla, New York

2007 - 2010 Secretary, Medical Staff of Westchester Medical Center, Valhalla, New York

2008 - Present Director, Children's Environmental Health Center of the Hudson Valley, Maria Fareri Children's Hospital and New York Medical College School of Public Health, Valhalla, New York

2008 - Present Member, Community Advisory Board- School of Health Sciences and Practice, New York Medical College, Valhalla, New York

2011 - 2014 President, Medical Staff of Westchester Medical Center, Valhalla, New York

2011 - Present Board Member (ex-officio)- Westchester Medical Center Foundation, Valhalla, New York

2012 - Present Member, Academic Policy Committee, School of Health Sciences and Practice, New York Medical College, Valhalla, New York

2015 - Present Director, Children's Environmental Health Center of the Hudson Valley, School of Health Sciences and Practice, New York Medical College, Valhalla, New York

2020 - 2021 Interim Vice President, Boston Children's Health Physicians, LLP, Valhalla, New York

2021 - Present Lovelace Fellow, New York Medical College, Valhalla, New York

2021 - Present President, Boston Children's Health Physicians, LLP, Valhalla, New York

LICENSURE AND CERTIFICATION:

1977 Diplomate, National Board of Medical Examiners

1978 New York State License Registration, #138965

1980 Massachusetts License Registration

1981 Certificate, American Board of Pediatrics, #2629

1986 Certificate, Pediatric Pulmonology, #37

1995 Recertification, Pediatric Pulmonology

2003 Recertification, Pediatric Pulmonology

2012 Recertification, Pediatric Pulmonology

2021 Recertification, Pediatric Pulmonology

AWARDS AND HONORS:

1969- 1976 Anna M. Vincent Trust Scholar

1981-1982 National Research Service Award, National Institutes of Health

1988-1989 President, Pediatric Society of New York Medical College

1991-1992 New York Medical College Senior Class Teaching Award

1994 Leadership Award, Caring Friends Fighting Cystic Fibrosis, New York Medical College

2000 President's Award, Westchester Medical Center

2000 Honoree, Breath of Fresh Air Gala, American Lung Association of the Hudson Valley

2010 Honoree, Cystic Fibrosis Foundation Greater New York Chapter Gala

2012 Public Health Leadership Award, Westchester County

MEMBERSHIP IN PROFESSIONAL SOCIETIES AND COMMUNITY OUTREACH:

1980 New York Academy of Sciences

1981 American Thoracic Society

1988 Fellow, American College of Chest Physicians
 1989 Fellow, American Academy of Pediatrics
 1990 Member, Pediatric AIDS Medical Advisory Panel Human Resources Administration, The City of New York
 1991 Board of Directors, The American Lung Association of the Hudson Valley
 1993 Member, Pediatric Pulmonary Training Directors Association
 1995 Member, Health Advisory Committee, Early Childhood Program, Westchester Community Opportunity Program, Hawthorne, NY
 2002 Member, Westchester County Advisory Asthma Council, White Plains, New York
 1997 Member, New York State Advisory Committee: Clinical Guidelines for the Diagnosis, Evaluation and management of Adults and Children with Asthma, NY State Department of Health Office of Managed Care, Albany, NY

HOSPITAL AND MEDICAL COLLEGE COMMITTEES:

1986-Present Pediatric Intensive Care Committee, Westchester Medical Center, Valhalla, New York
 1987- 1996 Infant Apnea Committee, Nyack Hospital, Nyack, New York
 1988- 1996 Pediatric Intensive Care Committee, Nyack Hospital, Nyack, New York
 1990 - 2005 Medical Ethics Committee, Westchester Medical Center, Valhalla, New York
 1991 – 1995 Chairman, Pediatric Intensive Care Committee, Westchester Medical Center, Valhalla, New York
 1991 -1992 Continuing Medical Education Subcommittee, New York Medical College, Valhalla, New York
 1992 -Present Member-at-Large, Executive Committee of the Medical Staff, Westchester Medical Center, Valhalla, New York
 1992-Present Faculty Senate, New York Medical College, Valhalla, New York
 1993-Present Advanced Technology Committee, Westchester Medical Center, Valhalla, New York
 1997 – 1998 Chairman, Committee on the Care of Adults with Pediatric Diseases, Department of Pediatrics, Westchester Medical Center, Valhalla, New York
 1999 Chairman, Committee on Triage in the Children's Hospital, Department of Pediatrics, Westchester Medical Center, Valhalla, New York
 1999-2004 Member, Alternative Pathways Committee, New York Medical College, Valhalla, New York
 1998- Present Member, Board of Directors, Medical Faculty Health Alliance, Valhalla, New York
 2002-Present Member, Financial Subcommittee, Federated Faculty Practice Plan, New York Medical College, Valhalla, NY
 2000-Present Member, Conflicts Resolution Committee, New York Medical College, Valhalla, New York
 2003-Present Member, Communication Committee, Westchester Medical Center, Valhalla, New York
 2004- Present Chairman, Finance Subcommittee, Medical Faculty Health Alliance, Valhalla, New York
 2007-2010 Vice President, Executive Committee of the Medical Staff, Westchester Medical Center, Valhalla, New York
 2007- Present Member, Bylaws Committee, Medical Staff, Westchester Medical Center, Valhalla, New York
 2009- Present Member, Curriculum Committee, School of Health Sciences and Practice, New York Medical College, Valhalla, New York
 2011-2014 Chairman of the Executive Committee of the Medical Staff, Westchester Medical Center, Valhalla, New York

EDUCATIONAL ACTIVITIES:

1969- 1972 Instructor and Assistant to the Director, Animal Research Laboratory, Cardiovascular Institute of Hahnemann Medical College and Hospital, Philadelphia, Pennsylvania
 1979- 1982 Instructor, Cardiopulmonary Resuscitation, American Heart Association
 1981- 1983 Instructor in Pathophysiology, Massachusetts College of Pharmacy and Allied Health Sciences, Boston, Massachusetts
 1982- 1983 Attending Physician, Medical Intensive Care Units, Children's Hospital and Medical Center, Boston, Massachusetts
 1982- 1983 Instructor, Introduction to Clinical Medicine, Harvard Medical School, Boston, Massachusetts
 1983- 1985 Director, Research and Education, CF, Pediatric Pulmonary, and GI Center, St. Vincent's Hospital and Medical Center of New York, New York, New York
 1985- 1990 Co-Director, Critical Care Education, Westchester Medical Center, Valhalla, New York
 1985 - Present Coordinator, summer research and clinical electives for first- and second-year medical students in Pediatric Pulmonology, New York Medical College, Valhalla, New York
 1985 - Present Coordinator, and author of curriculum for Pediatric Pulmonology conferences given to all third year

	medical students during their Pediatric Clerkship at all NYMC sites
1985- Present	Lecturer, Pediatric Pulmonology conferences given to all third year medical students during their Pediatric Clerkship at WMC, Valhalla, New York
1985 -Present	Coordinator and Preceptor for Pediatric Pulmonology elective for fourth year medical students, New York Medical College, Valhalla, New York
1985 - Present	Coordinator and Lecturer, Pediatric Pulmonology conference curriculum for Core Pediatric residents at all NYMC sites (WMC, Metropolitan, OLM)
1985 - 1996	Author, Pediatric Pulmonology section of quarterly house officer written examinations at all NYMC sites
1985- 1994	Coordinator, Pediatric Critical Care Teaching Rounds for Core Pediatric residents at WMC, Valhalla, New York
1985- Present	Teaching Rounds, Pediatric Intensive Care Unit at WMC, Valhalla, New York
1985- 1996	Coordinator, Pediatric Pulmonology Clinic conference, held weekly for Core Pediatric residents at Westchester Medical Center, Valhalla, New York
1988- Present	Director, Fellowship in Pediatric Pulmonology, New York Medical College and Westchester Medical Center, Valhalla, New York
1988- 1994	Mentor, Scarsdale Senior Student Elective Program, one student each year, Scarsdale, NY
1988- Present	Coordinator and participant, Journal Club in Pediatric Pulmonology at Westchester Medical Center and New York Medical College, Valhalla, New York
1988- Present	Coordinator and participant, Research Conference in Pediatric Pulmonology at Westchester Medical Center and New York Medical College, Valhalla, New York
1988- Present	Coordinator and participant, Cystic Fibrosis Center Team Conference at Westchester Medical Center and New York Medical College, Valhalla, New York
1988 - Present	Coordinator and participant, Respiratory Physiology Conference for Pediatric Pulmonology Fellows at Westchester Medical Center and New York Medical College, Valhalla, New York
1988 - Present	Coordinator and participant, Statistics and Research Techniques Conference series for Pediatric Pulmonology Fellows at Westchester Medical Center and New York Medical College, Valhalla, New York
1988- Present	Lecturer, "Pediatric Pulmonary Function Tests in Children," for Pediatric Pulmonology Fellows at Westchester Medical Center and New York Medical College, Valhalla, New York
1989- 1993	Lecturer, Epidemiology of Pediatric Lung Disease, Graduate School of Health Sciences, New York Medical College, Valhalla, New York
1991 - Present	Mentor, Marymount PreMedical Summer Program, Tarrytown, New York
1992 - Present	Nutrition and Cystic Fibrosis, Graduate School of Health Sciences, New York Medical College, Valhalla, New York
1998- Present	Host, Dinner for medical students considering Pediatrics, Sponsored by AMSA
2009 – Present	Mentor, MPH Students, School of Health Sciences and Practice, New York Medical College, Valhalla, New York

RECENT INVITED LECTURES AND CONTINUING MEDICAL EDUCATION LAST TEN YEARS)
(Supplied upon request)

GRANT SUPPORT (EXTERNAL FUNDING ONLY):

CF Foundation; Respiratory Heat and Water Exchange in Cystic Fibrosis; January 1984 - January 1986.

HMSS, Inc, Respiratory Water Regulation in Cystic Fibrosis; June 1990- June 1992.

Glaxo, Inc.; Ceftazidime Levels: Continuous versus Intermittent Infusion in patients with Cystic Fibrosis; July 1991 -June 1992.

CF Foundation; Phase III DNAase Study in Patients with Cystic Fibrosis; April 1992- March 1993.

Genentech, Inc.; RhDNAase in Hospitalized Patients with Cystic Fibrosis; November 1992- November, 1994.

Genentech, Inc.; Epidemiologic Protocol to Evaluate Pulmonary Function and Respiratory Infections in Patients with Cystic Fibrosis; April 1, 1993- March 31, 1995.

Caring Friends, NYMC Pediatric Pulmonary Research Fund; Effects of DNAase on REE in Patients with Cystic Fibrosis; July 1993 -June 1994.

Genentech, Inc; Open Label Use of Aerosolized rhDNAase in Cystic Fibrosis; April 1, 1993- March 31, 1994.

Genentech, Inc.; Study to Evaluate rhDNase Administered with Three Different Delivery Systems in Patients with Cystic Fibrosis; July 1, 1993- June 30, 1994.

Caring Friends, NYMC Pediatric Pulmonary Research Fund, Forced Expiratory Maneuvers in Children aged 3-5 Years; July 1993- June 1994.

Univax Biologics; Safety Evaluation of Hyperimmune IVIG in Patients with Cystic Fibrosis; September 1, 1994 - August 31, 1995.

Genentech, Inc; North American Cystic Fibrosis Epidemiologic Study; Co-Investigator, January 1994- January 2004.

Health Infusions, Inc.; Effects of Omega-3 Fatty Acid Supplementation in Cystic Fibrosis; Co-Investigator, July 1994- June 1996.

Genentech, Inc.; Phase IV Multicenter Study on Efficacy of Pulmozyme in Cystic Fibrosis; January 1, 1995- January 1, 1996.

Univax Biologicals; Phase II Multicenter Study on Efficacy and Safety of Hyperimmune IVIG in Patients with Cystic Fibrosis; Co- Investigator, January 1, 1995- October 30, 1996.

Medimmune, Inc.; Phase III Multicenter trial of an anti-RSV monoclonal Antibody in children with chronic lung disease; Co- Investigator, October 1, 1996 - September 30, 1997.

Astra-Zeneca Pharmaceuticals, Inc.; Phase II Multicenter trial and dosing study of the leukotriene Receptor Antagonist, Zafirlukast in Children with Asthma; November 1, 1996- December 31, 1997.

Medimmune, Inc.; Phase IV Multicenter trial of an anti-RSV monoclonal Antibody in children with Cystic Fibrosis under two years of age; Co-Investigator, November 1, 1998- October 31, 2000.

Hoffman LaRoche, Inc.; Multicenter trial of a neuraminidase inhibitor in healthy children with Influenza; Principal Investigator, December 1, 1998- November 30, 1999.

Hoffman LaRoche, Inc.; Multicenter trial of a neuraminidase inhibitor in children with asthma and Influenza; Principal Investigator, December 1, 1998- November 30, 1999.

Sepracor, Inc.; Phase IV open-label trial of Xopenex in children with asthma; Co-Investigator, November 1, 1998- May 1, 1999.

Cystic Fibrosis Foundation Multicenter study of two different dosing regimens for intravenous tobramycin in patients with cystic fibrosis; Co-investigator; September 1999- August 2001.

American Lung Association; Asthma Clinical Research Center of the American Lung Association, Principal Investigator, July 1, 1999- June 20, 2016.

Merck & Co., Inc, Effect of Montelukast on lung function in children with mild asthma, Principal Investigator, November 1, 1999- October 31, 2000.

Pathogenesis Corp; Open-label randomized trial with tobramycin solution for inhalation in cystic fibrosis patients with mild lung disease, Principal Investigator, May 2000 -April 2002.

American Lung Association; Study of inactivated influenza vaccine in asthmatics, Principal Investigator, July 2000- June 30, 2001.

Astra-Zeneca, L.L. P.; Safety and Efficacy study of Pulmicort Respules in infants 6-12 months of age with Asthma, Principal Investigator, July 1, 2000- June 30, 2001.

Cystic Fibrosis Association of Greater New York CF Young Adult Care Grant, January 1, 2002 – December 31, 2002.

American Lung Association, LODO: Effectiveness of low dose theophylline as Add-On Therapy in the treatment of Asthma, Principal Investigator, September, 2001-August 2003.

Investigator, September, 2001-August 2003.

Children's Hospital of Buffalo and the CF Foundation; Stool elastase in patients with CF: Misclassification of CF, Co-investigator,
May 2002-April 2003.

American Lung Association, The Leukotriene Modifier or Corticosteroid or Corticosteroid-Salmeterol Trial (LOCCS), Principal Investigator, January 2004 -December 2005.

American Lung Association, Trial of Asthma Patient Education (TAPE), Principal Investigator, January 2004-December 2006.

Corus Pharma, Inc, CP-AI-005: A phase 3, double blind, multicenter, multinational, randomized placebo-controlled trial evaluating Aztreonam Lysinate for inhalation in cystic fibrosis patients with pulmonary pseudomonas aeruginosa. Site co-PI, May 1, 2005- April 30, 2007.

Cystic Fibrosis Foundation; EPIC 001: Effectiveness and safety of intermittent antimicrobial therapy for the treatment of new-onset pseudomonas aeruginosa airway infection in young patients with cystic fibrosis, Site Co-PI, May 1, 2005 – April 30, 2007.

Cystic Fibrosis Foundation; EPIC 002: Longitudinal assessment of risk factors for and impact of pseudomonas aeruginosa acquisition and early- anti-pseudomonas treatment in children with cystic fibrosis, Site Co-PI, May 1, 2005- April 30, 2016.

Chiron Pharmaceuticals; TPI002: A randomized three-cycle, two-arm, multicenter Phase III trial to assess the safety and efficacy of tobramycin powder for inhalation (TPI) in CF patients 6-20 years of age, site Co-PI, June 1, 2005- May 31, 2007.

Chiron Pharmaceuticals; TPI003: A randomized, open-label, phase II trial to demonstrate the safety and efficacy of TPI powder administered by the Nektar T-326 DPI device in cystic fibrosis patients greater than 6 years of age. site Co-PI, June 1, 2005- May 31, 2007.

Medimmune Inc; Beta2 receptor polymorphisms in children with RSV bronchiolitis, Co-PI, July 1, 2005- June 30, 2006.

Inspire Pharma; Inspire 08-108 (Tiger-1) Phase III double-blind, placebo-controlled trial of Denusofol in patients with Cystic Fibrosis, site -PI September 2006- August 2008.

Cystic Fibrosis Foundation; AZ0004: Multicenter, multinational, randomized, placebo-controlled trial of azithromycin in subjects with cystic fibrosis and culture negative for pseudomonas aeruginosa. December 2006- December 2009.

American Lung Association and NIH SARCA: Study of Acid Reflux in Asthma; December 2006- November 2010.

Cystic Fibrosis Foundation; Nitrooxidative Stress in Asthma. Maria Fareri Children's Hospital Foundation, (Co-PI), May 2007- April 2009. Clinical Research Facilitation Award. December 2006- November 2008.

Agency for Health Care Research and Quality Learning from a Distance: A Practical Model for Transforming Childhood Asthma Care, (Consultant) - July 2007- June 2009.

Gilead Sciences Expanded Access Program for Inhaled Aztreonam for Cystic Fibrosis; January 2008 - January 2010.

MPEX-204: Phase 2 Multicenter, randomized, double-blind, placebo-controlled study ofMP-376 (inhaled levoquin) for cystic fibrosis, October 2008- September 2010.

Inspire 08-110 (Tiger-2) Phase III double blind placebo-controlled trial of Denusofol in patients with Cystic Fibrosis, Inspire Pharma., September 2008- August 2010.

American Lung Association; MeChis: Methacholine Challenge Testing and the effects of high dose inhaled steroids in

asthma. November 2008- October 2009.

Children's Environmental Health Center Support Grant. Westchester Community Foundation, November 11, 2008-November 10, 2009

Center for Pediatric Environmental Health Grant-Alfred E. Smith Memorial Foundation, December 16, 2008 - December 15, 2009.

Therapeutics Development Center Grant, Cystic Fibrosis Foundation, \$75,600/year. January 1, 2009 –December 31, 2016.

Children's Environmental Health Center Contract-New York State Department of Health, March 1, 2009- February 28, 2010

Vertex VX08-770-104: Phase II double-blind placebo-controlled trial of a CFTR potentiator in patients with Cystic Fibrosis, Vertex Pharma, December 1, 2009-November 30,2011

PTC 124-Phase II double-blind placebo-controlled trial of an orally absorbed treatment for CF patient's with premature stop codons, PTC Therapeutics, December 1, 2009-November 30, 2012.

Children's Environmental Health Center Support Grant. Westchester Community Foundation, November 11, 2009 - November 10, 2010

SOYA: Study of Genestein, a Soy Isoflavone, given to patients with poorly controlled asthma. A double-blind, multicenter randomized controlled trial, American Lung Association and NHLBI/NIH, December 2009 - November 2011.

STAN-Multicenter randomized placebo-controlled trial of nasal corticosteroids in patients with poorly controlled asthma, American Lung Association and NHLBI/NIH, January 2010-December 2011.

APR- the Asthma Patient Registry, American Lung Association Asthma Clinical Research Center Network. December 10, 2009 – Ongoing.

AHRQ R01HL094589-01A1 (Co-1) Improving Asthma Outcomes through Spirometry distance Learning. A Web based educational program designed to test whether asthma control is improved with the introduction of spirometry into primary care, April 2010 -March 2014.

Children's Environmental Health Center Support Grant. Westchester Community Foundation, November 11 2010-November 10, 2011.

MPEX Pharma -207-Phase III, multicenter double-blind trial of MP-376 in Cystic Fibrosis, December 2010-December 2012.

MPEX Pharma-209-Phase III multicenter double blind trial comparing MP-376 to inhaled tobramycin in cystic fibrosis, October 2009 -December 2012.

Primary Care Pediatric Asthma Preceptorship Support Grant: Stony Wold- Herbert Foundation, January 1, 2012 – December 31, 2012.

Children's Environmental Health Center Support Grant. Westchester Community Foundation, November 11, 2011-November 10, 2012

CFF Therapeutic Development Network: the CF FC Trial: A long term prospective Safety study of the incidence of and risk factors for fibrosing colonopathy in US Patients with CF treated with pancreatic enzyme replacement therapy. 4/9/2012 – Ongoing

Vertex VX11-770-110: Phase 3 Study of Ivacaftor in CF Subjects with the R117H mutation. Vertex Pharma, May 2012-April 2014.

LASST: Long Acting Beta Agonist Step Down Study, A 56 week multi-center, prospective, randomized, three-arm parallel group comparative effectiveness study comparing three approaches to care of patients with asthma well-controlled for three months on combination ICS/LABA. Sponsored by

American Lung Association and GSK, March 2012-February 2015.

American Lung Association and NHLBI/ NIH; CPAP: Effect of Positive Airway Pressure on Reducing Airway reactivity in Patients with Asthma, September 2012 – August 2014.

Vertex VX12-770-112: Open label follow-up study of patients enrolled in phase 3 trial of Ivacaftor in patients with CF and the R117H mutation, Vertex Pharma, April 2013-March 2015.

Westchester Community Foundation; Children's Environmental Health Center Support Grant., January 1, 2012- December 31, 2013.

Kalobios Pharma-Phase II, Randomized, double-blind, repeat dose stud of KBOO IA in Cystic Fibrosis, October 10, 2012 –March 1, 2015.

American Lung Association; SAPS: SCS: Smoking Asthmatics Pilot Study and Smoking Asthmatic Cohort Study: Asthma Clinical Research Center Network. January 14, 2013- September 1, 2016.

Novartis Pharma: TIP vs TIP: A 24-week open-label parallel-group, intervention phase IV study comparing tobramycin inhalation powder (TIP) administered once daily continuously versus TIP administered BID in 28 day on/ 28 day off cycles for the treatment of pulmonary pseudomonas in cystic fibrosis. March 10, 2014 – March 9, 2016.

Stony Wold Herbert Foundation: Close the Gap: A Community-Based Asthma Education and Prevention Program for Families, Public Health professionals and Primary Care Providers, -January 1, 2013-December 31, 2013.

Vertex VX12-809-103: Phase III, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of lumacaftor in combination with ivacaftor in subjects with CF homozygous for delF508 mutation of CFTR. September 1, 2012 – July 14, 2014.

Vertex VX12-809-105: Phase III, rollover study to evaluate the safety & efficacy of lumacaftor combined with ivacaftor in patients with CF either homozygous or heterozygous for the F508del-CFTR Mutation, October 1, 2013-September 30, 2016.

Novartis Pharma-Protocol CTBM1 OOC2304: Randomized double-blind, placebo-controlled, cross-over multi-center study to assess the efficacy & safety of inhaled tobramycin nebulizer solution for the treatment of infants and young children with cystic fibrosis, October 1, 2013-September 30, 2016.

Novartis Pharma: Novartis Human Factors Assessment: A multi-center, human factors engineering (HFE) usability study in cystic fibrosis patients to validate the approved instructions for use (IFU) of TOBI Podhaler. September 15, 2014 – May 2015.

American Lung Association; REACH: Resistant Airway Obstruction in Children. American Lung Association Airways Clinical Research Center; Network. January 12, 2015 – January 11, 2017.

CFE Therapeutic Development Network: The Prospect Trial: Two-part multicenter prospective longitudinal study of CFTR-Dependent Disease Profiling in Cystic Fibrosis. May 1, 2015-April 30, 2017.

Seattle Children's Hospital and the CF TDN: The Optimize Trial: Optimizing treatment for early pseudomonas aeruginosa infection in cystic fibrosis: SA multi-center placebo-controlled, double-blinded randomized trial. April 1, 2015 – March 31, 2017.

PTC Therapeutics: A Phase 3 efficacy and safety study of Ataluren (PTC124) in patients with nonsense mutations and cystic fibrosis. May 15, 2015 – May 14, 2017.

Vertex Pharma: VX14-661-108: a phase 3, randomized double-blind, placebo-controlled, crossover study to evaluate the efficacy and safety of Ivacaftor and VX-661 in combination with Ivacaftor in subjects 12 years and older with CF, heterozygous for the F508del-CFTR Mutation and a second allele with a CFT Mutation predicted have residual function. April 15, 2015 – April 14, 2017.

Pharmaxis, Ltd: Long term administration of inhaled mannitol in cystic fibrosis – a safety and efficacy trial in adult cystic fibrosis subjects. April 1, 2015 – March 30, 2017.

Novartis Pharma: A 26 week, randomized, active-controlled safety study of double-blind formoterol fumarate in free

combination with an inhaled corticosteroid versus an inhaled corticosteroid in adolescent and adult patients with persistent asthma. June 1, 2015 – May 31, 2017.

American Lung Association; ACE: Anxiety and COPD evaluation. American Lung Association Airways Clinical Research Center Network. July 28, 2015- June 27, 2017

Corbus Pharma: JBT101-CF-001. A Phase 2, double-blind, randomized, placebo-controlled multicenter study to evaluate safety, tolerability, pharmacokinetics, and efficacy of JBT-101 in CF. January 1, 2016- December 2017.

Vertex Pharma. Vertex 15-371-101. A Phase 2A Randomized, double-blind, placebo-controlled incomplete block, crossover study to evaluate the safety and efficacy of VX371 in subjects with CF and homozygous for the F608del-CFTR Mutation. October 20, 2016 – October 30, 2017.

Vertex Pharma. Vertex 661-114. Phase 3b, randomized, double-blind, placebo-controlled parallel group study to assess the safety and efficacy and tolerability of tezacaftor/ivacaftor in CF. 7/19/2016 – October 27, 2018.

Columbia University and the Cystic Fibrosis Foundation. SPARK: Pilot study of educational materials regarding clinical research for patients with CF and their families. March 13, 2017 – December 10, 2018.

Phillips (Respironics). SPRTE: Single site progressive research study testing a connected ecosystem of asthma products for children and parents. April 3, 2017 – April 8, 2019.

Gilead Pharma. Alpine 2. Randomized, double-blind, phase 3b trial to evaluate the safety and efficacy of 2 treatment regimens of Aztreonam 75 mg powder and solvent for nebulizer solution / Aztreonam for inhalation solution (AZLI) in pediatric subjects with cystic fibrosis (CF) and new onset respiratory tract pseudomonas aeruginosa (PA) infection/colonization. November 13, 2017 – May 29, 2020.

Phillips (Respironics). Protocol HRC-17067-HCPED-CC. Engineering Evaluation for the Helix Ventilator. October 9, 2017 – October 8, 2019.

Proteostasis Pharma. PTI 801-01. A multi-center, randomized, placebo-controlled phase I two-part study of PTI-801 in health controls and patients with CF. October 26, 2017 – October 25, 2019.

Corbus Pharma. Corbus 2B. A multicenter, randomized, double-blind, placebo-controlled phase 2 trial of Lenabasum in CF. October 27, 2017 – October 26, 2019.

Vertex Pharma. VX 445-102. A phase 3 randomized, double-blind, controlled study of VX-445 in CF patients who are heterozygous for the F508delCFTR mutation and a second minimal function mutation. . February 26, 2018 – February 25, 2020.

Vertex Pharma. VX 445-103. A phase 3, randomized, double-blind, controlled study of VX-445 in CF patients homozygous for F508delCFTR mutation. May 22, 2018 – May 21, 2019.

AstraZeneca Pharma. Chronicle. A longitudinal prospective observational study of the characteristics, treatment patterns, and health outcomes of individuals with severe asthma in the United States. October 2, 2019 – Ongoing.

AstraZeneca Pharma. Navigator. A multicentre, randomized, double-blind, placebo controlled, parallel group, phase 3 study to evaluate the efficacy and safety of Tezepelumab in adults and adolescents with severe uncontrolled asthma. May 14, 2018 – Ongoing.

Calithera Pharma. CX-280-202. A phase 1b randomized, double-blind, placebo-controlled trial to evaluate the safety of CB-280 in patients with cystic fibrosis. March 16, 2020 – Ongoing.

Children's Health Translational Science Institute of New York Medical College. ROCAS. Resistant airflow obstruction in children with asthma; co-investigator. October 10, 2016 – Ongoing.

Corbus Pharma. JBT101-CF-002. A multicenter, randomized, double-blind, placebo-controlled phase 2 trial to evaluate efficacy and safety of Lenabasum in cystic fibrosis. December 11, 2017 – December 14, 2020.

Cystic Fibrosis Foundation. BEGIN. A prospective study to evaluate the biological and clinical effects of significantly corrected CFTR function in infants and young children. April 23, 2020 – Ongoing.

Cystic Fibrosis Foundation. CFFC-OB-11. A long-term prospective observational safety study of the incidence of and risk factors for fibrosing colonopathy in US patients with cystic fibrosis treated with pancreatic enzyme replacement therapy: A harmonized protocol across sponsors. April 9, 2012 – November 17, 2020.

Cystic Fibrosis Foundation. CHEC-SC. Characterizing CFTR modulated changes in sweat chloride and their association with clinical outcomes. November 22, 2017 – Ongoing.

Cystic Fibrosis Foundation. PROMISE-OB-18. A prospective study to evaluate biological and clinical effects of significantly corrected CFTR function. January 4, 2019 – Ongoing.

Cystic Fibrosis Foundation. SIMPLIFY. A master protocol to test the impact of discontinuing chronic therapies in people with cystic fibrosis on highly effective CFTR modulator therapy. May 27, 2020 – Ongoing.

Cystic Fibrosis Foundation. STOP-2. Standardized treatment of pulmonary exacerbations II. April 10, 2017 – June 23, 2020.
George Washington University. ALPS. Childhood pulmonary complications in a birth cohort after a randomized trial of antenatal corticosteroids. September 6, 2016 – Ongoing.

American Lung Association. SCAO: Sweat chloride and airways obstruction. July 2021 – June 2024.

Armata Pharma. Swarm: Double blind randomized placebo-controlled single and multiple ascending dose study to evaluate the safety and tolerability of AP-PA02 Multi-phage therapeutic candidate for inhalation in subjects with cystic fibrosis and chronic pulmonary pseudomonas. November 2021 – October 2023.

Vertex Pharma. VX20-121-102. A phase 3, randomized, double-blind, controlled study evaluating the efficacy and safety of CV-121 combination therapy in subjects with cystic fibrosis who are heterozygous for F508del and a minimal function mutation. July 2021 – June 2023.

University of Massachusetts and PCORI. Rho: Implementation of effective home oxygen weaning strategies in premature infants. June 2021 – July 2024.

Aridis Pharma. A Phase 1/2a randomized, double, blind, two-part, dose ascending, multicenter study of the safety and pharmacokinetics of AR-501 (gallium citate), administered via inhalation in healthy adults and P. Aeruginosa infected cystic fibrosis subjects. June 2021 – June 2023.

Touro College and University. BALI-RAGE: Biomarkers in acute lung injury including receptor for advanced glycation end products. May 2020 – May 2022.

PUBLICATIONS:

PEER-REVIEWED ARTICLES:

1. Dozor AJ, Bettinger J, O'Riordan AC, Kingsley B, Eshaghpour E. Spectral Analysis of Heart Sounds in Children. *Audio Engineering Society* 1975; 52:1078.
2. Naeye RL, Dozor AJ, Tafari N, Ross SM: Epidemiological Features of Perinatal Death Due to Obstructed Labor in Addis Ababa. *British J. Obstetr and Gynecology* 1977; 84:747-750.
3. McLaughlin FJ, Dozor AJ: Cold Air Challenge in Children. *Pediatrics* 1983; 72:503-509.
4. Dozor AJ, Treves S: Iridium-191m Exercise Angiocardiology in Patients with Cystic Fibrosis, International Symposium on Single Photon Ultrashort-Lived Radionuclides, Dept. of Energy and Pan American Health Organization, May 1983.
5. Geggel RL, Dozor AJ, Fyler DC, Reid LM: Effect of Vasodilators at Rest and during Exercise in Young Adults with Cystic Fibrosis and chronic cor pulmonale. *Am Rev Respir Dis* 1985; 131:531-539.
6. Newman LJ, Russe J, Glassman MS, Berezin S, Halata MS, Medow MS, Dozor AJ, Schwarz SM: Patterns of Gastroesophageal Reflux (GER) in Patients with Apparent Life-Threatening Events. *Journal of Pediatric Gastroenterology and Nutrition* 1986; 8: 157-160.
7. See CC, Newman LJ, Berezin S, Glassman, MS, Medow MS, Dozor AJ, Schwarz SM: Gastroesophageal

- reflux-induced hypoxemia in infants with apparent life-threatening events. *Am Journal of Diseases of Children* 1989; 143:951-954.
8. Berezin S, Ruddy RM, Dozor AJ, Newman L: Hypoelectrolytemia, hypovolemia and alkalosis in cystic fibrosis with wood-burning stove in winter. *Pediatric Emergency Care* 1989; 5:189-190.
 9. Dozor AJ: Cystic Fibrosis and the Primary Care Pediatrician. *Child Hosp Quarterly* 1990; 2:131-135.
 10. Glassman MS, Dozor AJ and Newman LJ: Gastroesophageal Reflux in Neurologically Impaired Children: Perioperative Evaluation and Management. *Southern Medical Journal*, 1992; Vol. 85, 3:289-292.
 11. Amin N, Dozor AJ: Emergency management of acute asthma in children. *Asthma Management* 1992; 1:28-33.
 12. Amin N, Dozor AJ: Effects of administration of aerosolized human deoxyribonuclease on resting energy expenditure in patients with Cystic Fibrosis. *Pediatric Pulmonology* 1994; 18:150-154.
 13. Kanengiser, S, Dozor AJ: Forced Expiratory Maneuvers in Children Aged 3- 5 Years. *Pediatric Pulmonology* 1994; 18:144-149.
 14. Fuchs, HJ, et al. and the Pulmozyme Study Group: (Dozor AJ) Aerosolized Recombinant Human DNase Reduces Respiratory Exacerbations and Improves Pulmonary Function in Patients with Cystic Fibrosis. *New Eng J Med* 1994; 331:637-42.
 15. Neglia, et al and the Cystic Fibrosis Cancer Study Group (Dozor AJ). Cancer Risk Among Patients with Cystic Fibrosis. *New Eng J Med* 1995; 332:494-9.
 16. Schroeder SA, Beneck D, and Dozor AJ. Spontaneous pneumothorax in children with AIDS. *Chest* 1995. 108:1173-76.
 17. Fiel, SB, et al and the Pulmozyme rhDNase study group. Comparison of three jet nebulizer aerosol delivery systems used to administer recombinant human DNase I to patients with cystic fibrosis. *Chest* 1995; 108:153-156.
 18. Nitihara J, Dozor AJ, Schroeder SA, Rifkinson-Mann S. Apnea as a presenting sign of hydrocephalus. *Pediatrics* 1996; 97:1-2.
 19. Boyer J, Dozor AJ, Brudnicki A, Slim M, Paliotta M, Kwark HE. Extralobar pulmonary sequestration masquerading as a congenital pleural effusion. *Pediatrics* 1996; 97:115-117.
 20. Boyer J, Amin N, Taddonio R, and Dozor AJ. Evidence of airway obstruction in children with idiopathic scoliosis. *Chest* 1996; 109:1532-35.
 21. O'Donohue WJ and the NAMDRC Consensus Group (Dozor, AJ). Guidelines for the use of nebulizers in the home and at domiciliary sites. *Chest* 1996; 109:814-20.
 22. Gjonaj ST, Lowenthal DB, Stringel G, and Dozor AJ. Recurrent pneumonia, asthma and respiratory arrest due to an endotracheal tumor. *Pediatrics* 1997;99(4):604-605.
 23. Wilmott, RW, Amin RS, Colin AA, De Vault, A, Dozor, AJ, et.al. Aerosolized recombinant human DNase in hospitalized cystic fibrosis patients with acute pulmonary exacerbations. *Am J Resp Crit Care Med* 1996; 153: 1914-1917.
 24. Lowenthal DB and Dozor AJ, Flexible Bronchoscopy in Infants and Children. *Emergency and Office Pediatrics* 1997; (10): 40-43.
 25. Krishnan S, Amin N, Stewart J, Dozor AJ. Electrocardiographic prediction of hyperinflation in children. *Am J Respir Crit Care Med* 1997;156; 2011-2014.
 26. Gjonaj ST, Lowenthal DB, Dozor AJ. Nebulized lidocaine administered to infants and children undergoing flexible bronchoscopy. *Chest* 1997; 112:1665-69.
 27. Krishnan S, Amin N, Dozor AJ, Stringel G. Urokinase in the management of complicated parapneumonic effusions in children. *Chest* 1997; 112:1579-83.

28. Sadeghi H, Lowenthal DB, Dozor AJ. Evaluation and management of infants after apparent life-threatening events. *Emergency and Office Pediatrics* 1998; 11(1): 5-12.
29. Sadeghi H, Lowenthal DB, Dozor AJ. Inspiratory flow limitation in children with bronchopulmonary dysplasia. *Pediatric Pulmonology* 1998; 26:167-172.
30. Sadeghi H, Lowenthal DB, Dozor AJ. Sudden onset of pulmonary edema in an otherwise healthy infant. *Emergency and Office Pediatrics* 1998; 11(4): 154-156.
31. Stringel G, Amin N, Dozor AJ. Video-assisted thoracoscopy in the management of recurrent spontaneous pneumothorax in the pediatric population. *Journal of the Society of Laparoendoscopic Surgeons* 1999; 3: 113-116.
32. Sadeghi H, Stringel G, Amin N, Dozor AJ. Unsuspected foreign body aspiration and asthma in children. 1999 *Emergency and Office Pediatrics* 1999; 12(4): 126-129.
33. Castro M, Dozor AJ, Fish, J, et al and the American Lung Association Asthma Clinical Research Centers. The safety of inactivated influenza vaccine in adults and children with asthma. *N Eng J Med* 2001; 345: 1529-36.
34. Holbrook JT, Wise, RA, Gerald LB for the American Lung Association Asthma Clinical Research Centers (including Dozor AJ). Drug distribution for a large crossover trial of the safety of inactivated influenza vaccine in asthmatics. *Control Clin Trials* 2002; 23:87-92.
35. Akanli L, Lowenthal D, Gjonaj S, Dozor AJ. Plasma and red blood cell zinc in cystic fibrosis. *Pediatric Pulmonology* 2003; 35:2-7.
36. Lee C, Dozor AJ. Do you believe milk makes mucus? *Arch Pediatr Adolesc Med* 2004; 158: 601-603.
37. Miller RL, Cheng M, DiMango EA, Geromanos K, Rothman PB, and the American Lung Association Asthma Clinical Research Centers (including Dozor AJ). T-cell responses and hypersensitivity to influenza and egg antigens among adults with asthma immunized with the influenza vaccine. *J Allergy Clin Immunol* 2003; 112:606-8.
38. Assefa D, Amin N, Dozor AJ. Effect of deep inspiration on airway caliber in children with asthma. *Pediatric Pulmonology* 2004; 38(5):406-412.
39. Hanania NA, Sockrider M, Castro M, Holbrook JT, Tonascia J, WiseR, and Atmar RL for the American Lung Association Asthma Clinical Research Centers (including Dozor AJ). Immune response to influenza vaccination in children and adults with asthma: Effect of corticosteroid therapy. *J Allergy Clin Immunol* 2004; 113:717-24.
40. Smith LJ, Holbrook JT, Wise RA, Blumenthal M, Dozor AJ, Mastronarde J, Williams L, and the American Lung Association Asthma Clinical Research Centers. Dietary intake of soy genistein is associated with lung function in patients with asthma. *J Asthma* 2004; 41(8); 833-843.
41. Dozor AJ. Spacer Crusader. *The Lancet* 2005; 365:572.
42. Dozor AJ. A practical guide to managing asthma in children. *J Respir Dis* 2005; 26 (8): 348-358.
43. Krishnan S, Banquet A, Newman L, Katta U, Patil A, Dozor AJ. Lung lesions in children with Crohn's disease presenting as nonresolving pneumonias and response to infliximab therapy. *Pediatrics* 2006. 117:1440-1443.
44. Lima JJ, Holbrook JT, Wang J, Sylvester JE, Blake KV, Blumenthal MN, Castro M, Hanania N, WiseR and the American Lung Association Asthma Clinical Research Centers (including Dozor, AJ). The C523A beta2 adrenergic receptor polymorphism associates with markers of asthma severity in African Americans. *J Asthma*. 2006; 43(3): 185-91.
45. Dixon AE, Shade DM, Cohen RI, Skloot GS, Holbrook JT, Smith LJ, Lima JJ, Allayee H, Irvin CG, Wise RA; American Lung Association-Asthma Clinical Research Centers (including Dozor AJ). Effect of obesity on clinical presentation and response to treatment in asthma. *J Asthma*. 2006; 43(7):553-8.
46. Irvin C, Kaminsky D, Anthonisen N, Castro M, Hanania N, Holbrook J, Lima J, WiseR. (Including Dozor AJ, Amin N.) Clinical trial of low-dose theophylline and montelukast in patients with poorly controlled

asthma. *Amer J Respir Crit Care Med* 2007; 175:235-242.

47. Assefa D, Amin N, Stringel G, Dozor AJ. Use of decubitus radiographs in the diagnosis of foreign body aspiration in young children. *Pediatric Emergency Care* 2007; 23(3); 154-157.
48. American Lung Association Asthma Clinical Research Centers (including Dozor AJ). Randomized comparison of strategies for reducing treatment in mild persistent asthma. *N Eng] J Med* 2007; 356(20): 2027-2039.
49. American Lung Association Asthma Clinical Research Centers, Mastronarde JG, Anthonisen NR, Castro M, Holbrook JT, Leone FT, Teague WG, Wise RA (including Dozor AJ). Efficacy of esomeprazole for treatment of poorly controlled asthma. *N Eng] J Med*. 2009; 360(15):1487-99.
50. Mastronarde JG, Wise RA, Shade DM, Olopade CO, Scharf SM; American Lung Association Asthma Clinical Research Centers. (Including Dozor AJ). Sleep quality in asthma: results of a large prospective clinical trial. *J Asthma*. 2008; 45(3):183-9.
51. Schechter MS, McColley AS, Silva S, Haselkorn T, Konstan MW, Wagener JS; Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis (including Dozor AJ). North American Scientific Advisory Group for ESCF. Association of socioeconomic status with the use of chronic therapies and healthcare utilization in children with cystic fibrosis. *J Pediatr* 2009; 155(5):634-9.
52. Newport S, Amin N, Dozor AJ. Exhaled breath condensate pH and ammonia in cystic fibrosis and response to treatment of acute pulmonary exacerbations. *Pediatric Pulmonology* 2009; 44(9):866-72.
53. Stone A, Quittell L, Zhou J, Alba L, Bhat M, Decelie-Germana J, Rajan S, Bonitz L, Welter JJ, Dozor AJ, Gherson I, Lowy FD, Saiman L. *Staphylococcus aureus* nasal colonization among pediatric CF patients and their household contacts. *Pediatr Infect Dis J* 2009; 28(10):895-899.
54. Wise RA, Bartlett SJ, Brown ED, Castro M, Cohen R, Holbrook JT, Irvin CG, Rand CS, Sockrider MM, Sugar EA; American Lung Association Asthma Clinical Research Centers (including Dozor AJ). Randomized trial of the effect of drug presentation on asthma outcomes: the American Lung Association Asthma Clinical Research Centers. *J Allergy Clin Immunol* 2009; 124(3):436-44, 444e1-8.
55. DiMango E, Holbrook JT, Simpson E, Reibman J, Richter J, Narula S, Prusakowski N, Mastronarde JG, Wise RA; American Lung Association Asthma Clinical Research Centers (including Dozor AJ). Effects of asymptomatic proximal and distal gastroesophageal reflux on asthma severity. *Am J Respir Crit Care Med*. 2009 Nov 1;180(9):809-16. Epub 2009 Aug 6. PMID: 19661245.
56. Bartlett JR, Friedman KJ, Ling SC, Pace RG, Bell SC, Bourke B, Castaldo G, Castellani C, Cipolli M, Colombo C, Colombo JL, Debray D, Fernandez A, Lacaille F, Macek M Jr, Rowland M, Salvatore F, Taylor CJ, Wainwright C, Wilschanski M, Zemkova D, Hannah WB, Phillips MJ, Corey M, Zielenski J, Dorfman R, Wang Y, Zou F, Silverman LM, Drumm ML, Wright FA, Lange EM, Durie PR, Knowles MR; Gene Modifier Study Group (including Dozor AJ). Genetic modifiers of liver disease in cystic fibrosis. *JAMA* 2009; 302(10):1076-83.
57. Treggiari MM, Rosenfeld M, Mayer-Hamblett N, Retsch-bogart G, Gibson RL, Williams J, Emerson J, Kronmal RA, Ramsety BW; EPIC Study Group (including Dozor AJ). Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study. *Contemp Clin Trials* 2009; 30(3):256-68.
58. Dixon AE, Sugar EA, Zinreich SJ, Slavin RG, Corren J, Naclerio RM, Ishii M, Cohen RI, Brown ED, Wise RA, Irvin CG; American Lung Association-Asthma Clinical Research Centers (including Dozor AJ). Criteria to screen for chronic sinonasal disease. *Chest*. 2009 Nov; 136(5):1324-32.
59. Saiman L, Anstead M, Mayer-Hamblett N, Lands LC, Kloster M, Hocevar-Trnka J, Goss CH, Rose LM, Burns JL, Marshall BC, Ratjen F; AZ0004 Azithromycin Study Group (including Dozor AJ). Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with *Pseudomonas aeruginosa*: a randomized controlled trial. *JAMA* 2010; 303(17):1707-15.
60. Rosenfeld M, Emerson J, McNamara S, Joubran K, Retsch-Bogart G, Graff GR, Gutierrez HH, Kanga JF, Lahiri T, Noyes B, Ramsey B, Ren CL, Schechter M, Morgan W, Gibson RL; EPIC Study Group Participating Clinical Sites (including Dozor AJ). Baseline characteristics and factors associated with nutritional and pulmonary status at enrollment

in the cystic fibrosis EPIC observational cohort. *Pediatr Pulmonol* 2010; 45(9):934-44.

61. Dozor AJ. The role of oxidative stress in the pathogenesis and treatment of asthma. *Ann N Y Acad Sci* 2010; 1203:133-137.
62. Accurso FJ, Moss RB, Wilmott RW, Anbar RD, Schaberg AE, Durham TA, Ramsey BW; the TIGER-I Investigator Study Group (including Dozor AJ). Denufosol Tetrasodium in Patients with Cystic Fibrosis and Normal to Mildly Impaired Lung Function. *Am J Respir Crit Care Med* 2011;183(5):627-34 PMID: 21169471
63. Geller DE, Flume PA, Staab D, Fischer R, Loutit JS, Conrad OJ; Mpex 204 Study Group (including Dozor AJ). Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with *Pseudomonas aeruginosa*. *Am J Respir Crit Care Med*. 2011;183(11):1510-6. PMID: 21471106
64. Assefa D, Amin N, Dozor AJ, Parton LA. Attenuated interleukin-8/leukocyte immunoresponse in preterm infants compared with term infants hospitalized with respiratory syncytial virus bronchiolitis: a pilot study. *Hum Immunol*. 2011; 72(9):708-11. PMID: 21683109.
65. Treggiari MM, Retsch-Bogart G, Mayer-Hamblett N, Khan U, Kulich M, Kronmal R, Williams J, Hiatt P, Gibson RL, Spencer T, Orenstein D, Chatfield BA, Froh DK, Burns JL, Rosenfeld M, Ramsey BW; Early *Pseudomonas* Infection Control (EPIC) Investigators (including Dozor AJ). Comparative efficacy and safety of 4 randomized regimens to treat early *Pseudomonas aeruginosa* infection in children with cystic fibrosis. *Arch Pediatr Adolesc Med* 2011; 165(9):847-56. PMID: 21893650.
66. Schechter MS, McColley SA, Regelman W, Millar SJ, Pasta DJ, Wagener JS, Konstan MW, Morgan WJ; Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis (including AJ). Socioeconomic status and the likelihood of antibiotic treatment for signs and symptoms of pulmonary exacerbation in children with cystic fibrosis. *J Pediatr* 2011; 159(5):819-824.
67. Writing Committee for the American Lung Association Asthma Clinical Research Centers: Holbrook JT, Wise RA, Gold BD, Blake K, Brown ED, Castro M, Dozor AJ, Lima JJ, Mastrorarde JG, Sackrider MM, Teague WG. Lansoprazole for children with poorly controlled asthma. A Randomized controlled trial. *JAMA* 2012; 307 (4): 373-381. PMID: 22274684.
68. Stout JW, Smith K, Zhou C, Solomon C, Dozor AJ, Garrison MM, Mangione-Smith R. Learning from a Distance: Effectiveness of Online Spirometry Training in Improving Asthma Care. *Acad Pediatr* 2012; (2):88-95. PMID: 22424397.
69. Mayer-I-Hamblett N, Kronmal RA, Gibson RL, Rosenfeld M, Retsch-Bogart G, Treggiari MM, Burns JL, Khan U, Ramsey BW; EPIC Investigators (including Dozor AJ). Initial *Pseudomonas aeruginosa* treatment failure is associated with exacerbations in cystic fibrosis. *Pediatr Pulmonol*. 2012; 47(2):125-34. PMID: 21830317.
70. Saiman L, Mayer-Hamblett N, Anstead M, Lands LC, Kloster M, Goss CH, Rose LM, Burns JL, Marshall BC, Ratjen F; AZ0004 Macrolide Study Team (including Dozor AJ). Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with *Pseudomonas aeruginosa*. *Pediatr Pulmonol*. 2012; 47(7):641-8. PMID: 22684984.
71. Sumino K, Sugar EA, Irvin CG, Kaminsky DA, Shade D, Wei CY, Holbrook JT, Wise RA, Castro M; American Lung Association Asthma Clinical Research Centers (including Dozor AJ.) Methacholine challenge test: diagnostic characteristics in asthmatic patients receiving controller medications. *J Allergy Clin Immunol*. 2012 Jul; 130(1):69-75. PMID: 22465214.
72. de La Riva-Velasco E, Krishnan S, Dozor AJ. Relationship between Exhaled Nitric Oxide and Exposure to Low-Level Environmental Tobacco Smoke in Children with Asthma on Inhaled Corticosteroids. *J Asthma*. 2012; 9(7):673-8. PMID: 22799435.
73. Boileau C, Guo DC, Hanna N, Regalado ES, Detaint D, Gong L, Varret M, Prakash SK, Li AH, d'Indy I, Braverman AC, Grandchamp B, Kwartler CS, Gouya L, Santos-Cortez RL, Abifadel M, Leal SM, Muti C, Shendure J, Gross MS, Rieder MJ, Vahanian A, Nickerson DA, Michel JB; National Heart, Lung, and Blood Institute (NI-ILBI) Go Exome Sequencing Project, (including Dozor A); Jondeau G, Milewicz DM. TGFB2 mutations cause familial thoracic aortic aneurysms and dissections associated with mild systemic features of Marfan syndrome. *Nat Genet*.

2012 Jul 8;44(8):916-21. PMID 22772371.

74. Emond MJ, Louie T, Emerson J, Zhao W, Mathias RA, Knowles MR, Wright FA, Rieder MJ, Tabor HK, Nickerson DA, Barnes KC; National Heart, Lung, and Blood Institute (NHLBI) GO Exome Sequencing Project (including Dozor A); Lung GO, Gibson RL, Bamshad MJ. Exome sequencing of extreme phenotypes identifies DCTN4 as a modifier of chronic *Pseudomonas aeruginosa* infection in cystic fibrosis. *Nat Genet.* 2012 Jul 8;44(8):886-9. PMID: 22772370.
75. Rosenfeld M, Emerson J, McNamara S, Thompson V, Ramsey BW, Morgan W, Gibson RL; EPIC Study Group (including Dozor AJ). Risk factors for age at initial *Pseudomonas* acquisition in the cystic fibrosis epic observational cohort. *J Cyst Fibros.* 2012 Sep; 11(5):446-53. PMID: 22554417.
76. Ratjen F, Durham T, Navratil T, Schaberg A, Accurso FJ, Wainwright C, Barnes M, Moss RB; TIGER-2 Study Investigator Group (including Dozor AJ). Long term effects of denufosal tetrasodium in patients with cystic fibrosis. *Cyst Fibros.* 2012 Dec;11(6):539-49. PMID: 22682898.
77. Lang JE, Holbrook JT, Wise RA, Dixon AE, Teague WG, Wei CY, Irvin CG, Shade D, Lima JJ; and the American Lung Association Asthma Clinical Research Centers (including Dozor AJ). Obesity in children with poorly controlled asthma: Sex differences. *Pediatr Pulmonol* 2013; 48(9):847-56. PMID: 23143849.
78. Fu W, O'Connor TD, Jun G, Kang HM, Abecasis G, Leal SM, Gabriel S, Altshuler D, Shendure J, Nickerson DA, Bamshad MJ; NHLBI Exome Sequencing Project (including Dozor AJ), Akey JM. Analysis of 6,515 exomes reveals the recent origin of most human protein-coding variants. *Nature.* 2013 Jan 10; 493(7431):216-20. PMID: 23201682.
79. Dozor AJ, Amler RW. Children's Environmental Health. *J Pediatr.* 2013 Jan; 162(1):6-7.e2. PMID: 23260307.
80. Lang JE, Dozor AJ, Holbrook JT, Mougey E, Krishnan S, Sweeten S, Wise RA, Teague WG, Wei CY, Shade D, Lima JJ; American Lung Association-Asthma Clinical Research Centers. Biologic mechanisms of environmental tobacco smoke in children with poorly controlled asthma: results from a multicenter clinical trial. *J Allergy Clin Immunol Pract.* 2013 Mar; 1(2):172-80. PMID: 24565456.
81. Norton N, Li D, Rampersaud E, Morales A, Martin ER, Zuchner S, Guo S, Gonzalez M, Hedges DJ, Robertson PO, Krumm N, Nickerson DA, Hershberger RE; National Heart, Lung, and Blood Institute GO Exome Sequencing Project and the Exome Sequencing Project Family Studies Project Team (including Dozor AJ). Exome Sequencing and genome-wide linkage analysis in 17 families illustrate the complex contribution of TTN truncating variants to dilated cardiomyopathy. *Circ Cardiovasc Genet* 2013 Apr; 6(2): 144-53. PMID: 23418287.
82. Mougey E, Lang JE, Allayee H, Teague WG, Dozor AJ, Wise RA, Lima JJ. ALOX5 Polymorphism associates with increased leukotriene production and reduced lung function and asthma control in children with poorly controlled asthma. *Clin Exp Allergy.* 2013; 43(5):512-20. PMID: 236005.
83. Johnsen JM, Aer PL, Morrison AC, Jiao S, Wei P, Haessler J, Fox K, McGee SR, Smith JD, Carlson CS, Smith N, Goerwinkle E, Kooperberg C, Nickerson DA, Rich SS, Green D, Peters U, Cushman M, Reiner AP; NHLBI Exome Sequencing Project (including Dozor AJ). Common and rare von Willebrand Factor (VWF) coding variants, VWF levels and factor VIII levels in African Americans; the NHLBI Exome Sequencing Project. *Blood* 2013; July 25; 122(4):590-7. PMID: 23690449
84. Morgan WJ, Wagener JS, Yegin A, Pasta DJ, Millar SJ, Konstan MW; Scientific Advisory Group, investigators; coordinators of the Epidemiologic Study of Cystic Fibrosis, (including Dozor AJ). Probability of treatment following acute decline in lung function in children with cystic fibrosis is related to baseline pulmonary function. *J Pediatr.* 2013 Oct; 163(4): 1152-7. e2. PMID: 23810128
85. Mayer-Hamblett N, Rosenfeld M, Treggiari MM, Konstan MW, Retsch-Bogart G, Morgan W, Wagener J, Gibson RL, Khan U, Emerson J, Thompson V, Elkin EP, Ramsey BW; EPIC; ESCF Investigators (including Dozor AJ). Standard care versus protocol-based therapy for new onset *Pseudomonas aeruginosa* in cystic fibrosis. *Pediatr Pulmonol.* 2013 Oct; 48(10):943-53. PMID: 23818295
86. O'Connor TO, Kiezun A, Bamshad M, Rich SS, Smith JD, Turner E; NHLBI GO Exome Sequencing Project; ESP Population Genetics, Statistical Analysis Working Group, Leal SM, Akey JM. Fine-scale patterns of population stratification confound rare variant association tests. *PLoS One* 2013 Jul 4; 8(7). PMID: 23861739.

87. Guo DC, Regalado E, Casteel DE, Santos-Cortez RL, Gong L, Kim JJ, Dyack S, Horne SG, Chang G, Jondeau G, Boileau C, Coselli JS, Li Z, Leal SM, Shendure J, Rieder MJ, Bamshad MJ, Nickerson DA; GenTAC Registry Consortium; National Heart, Lung, and Blood Institute Grand Opportunity Exome Sequencing Project, Kim C, Milewicz DM (including Dozor AJ). Recurrent gain-of-function mutation in PRKG1 causes thoracic aortic aneurysms and acute aortic dissections. *Am J Hum Genet.* 2013 Aug 8;93(2):398-404. PMID: 23910461.
88. Traeger N, Shi Q, Dozor AJ. Relationship between sweat chloride, sodium, and age in clinically obtained samples. *J Cyst Fibros.* 2013 Aug 2. PMID: 23916616.
89. Rosenthal EA, Ranchalis J, Crosslin DR, Burt A, Brunzell JD, Motulsky AG, Nickerson DA; NHLBI GO Exome Sequencing Project, Wijsman EM, Jarvik GP (including Dozor AJ). Joint linkage and association analysis with exome sequence data implicates SLC25A40 in hypertriglyceridemia. *Am J Hum Genet.* 2013 Dec 5;93(6):1035-45. PMID: 24268658.
90. Gordon AS, Tabor HK, Johnson AD, Snively BM, Assimes TL, Auer PL, Ioannidis JP, Peters U, Robinson JG, Sucheston LE, Wang D, Sotoodehnia N, Rotter JI, Psaty BM, Jackson RD, Herrington DM, O'Donnell CJ, Reiner AP, Rich SS, Rieder MJ, Bamshad MJ, Nickerson DA; NHLBI GO Exome Sequencing Project. (including Dozor AJ). Quantifying rare, deleterious variation in 12 human cytochrome P450 drug-metabolism genes in a large-scale exome dataset. *Hum Mol Genet.* 2014 Apr 15;23(8):1957-63. PMID: 24282029
91. Valsamis C, Krishnan S, Dozor AJ. The effects of low-level environmental tobacco smoke exposure on pulmonary function tests in preschool children with asthma. *J Asthma.* 2014 Sep; 51(7):685-90. PMID: 2457585.
92. Gill R, Krishnan S, Dozor AJ. Low-level environmental tobacco smoke exposure and inflammatory biomarkers in children with asthma. *J Asthma.* 2014 May;51(4):355-9. PMID:24580138.
93. Kerem E, Konstan MW, De Boeck K, Accurso FJ, Sermet-Gaudelus I, Wilschanski M, Elborn JS, Melotti P, Bronsveld I, Fajac I, Malfroot A, Rosenbluth DB, Walker PA, McColley SA, Knoop C, Quattrucci S, Rietschel E, Zeitlin PL, Barth J, Elfring GL, Welch EM, Branstrom A, Spiegel RJ, Peltz SW, Ajayi T, Rowe SM; Cystic Fibrosis Ataluren Study Group (include Dozor AJ). Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial. *Lancet Respir Med.* 2014 Jul;2(7):539-47. PMID: 24836205.
94. American Lung Association–Asthma Clinical Research Centers' Writing Committee: Dixon AE, Castro M, Cohen RI, Gerald LB, Holbrook JT, Irvin CG, Mohapatra S, Peters SP, Rayapudi S, Sugar EA, Wise RA (including Dozor AJ). Efficacy of nasal mometasone for the treatment of chronic sinonasal disease in patients with inadequately controlled asthma. *J Allergy Clin Immunol.* 2014 Aug 28. PMID: 25174863.
95. Kapadia SG, Wei C, Bartlett SJ, Lang J, Wise RA, Dixon AE; American Lung Association Asthma Clinical Research Centers (including Dozor AJ). Obesity and symptoms of depression contribute independently to the poor asthma control of obesity. *Respir Med.* 2014 Aug;108(8):1100-7. PMID: 24947900.
96. Tabor HK, Auer PL, Jamal SM, Chong JX, Yu JH, Gordon AS, Graubert TA, O'Donnell CJ, Rich SS, Nickerson DA; NHLBI Exome Sequencing Project, (including Dozor AJ), Bamshad MJ. Pathogenic variants for Mendelian and complex traits in exomes of 6,517 European and African Americans: implications for the return of incidental results. *Am J Hum Genet.* 2014 Aug 7;95(2):183-93. PMID: 25087612
97. Hurley EH, Krishnan S, Parton LA, Dozor AJ. Differences in perspective on prognosis and treatment of children with trisomy 18. *Am J Med Genet A.* 2014 Oct; 164A(10):2551-6. PMID: 25098974.
98. Lang JE, Holbrook JT, Mougey EB, Wei CY, Wise RA, Teague WG, Lima JJ, and the American Lung Association-Asthma Clinical Research Centers (including Dozor AJ). Lansoprazole is Associated with Worsening Asthma Control in Children with the *CYP2C19* Poor Metabolizer Phenotype. *Annals ATS.* First published online 06 Apr 2015 as DOI: 10.1513/AnnalsATS.201408-391OC.
99. Do R, Stitzel NO, Won HH, Jørgensen AB, Duga S, Angelica Merlini P, Kiezun A, Farrall M, Goel A, Zuk O, Guella I, Asselta R, Lange LA, Peloso GM, Auer PL; NHLBI Exome Sequencing Project, Girelli D, Martinelli N, Farlow DN, DePristo MA, Roberts R, Stewart AF, Saleheen D, Danesh J, Epstein SE, Sivapalaratnam S, Hovingh GK, Kastelein JJ, Samani NJ, Schunkert H, Erdmann J, Shah SH, Kraus WE, Davies R, Nikpay M, Johansen CT, Wang J, Hegele RA, Hechter E, Marz W, Kleber ME, Huang J, Johnson AD, Li M, Burke GL, Gross M, Liu Y, Assimes TL, Heiss G, Lange EM, Folsom AR, Taylor HA, Olivieri O, Hamsten A, Clarke R, Reilly DF, Yin W, Rivas MA, Donnelly P, Rossouw JE, Psaty BM, Herrington DM, Wilson JG, Rich SS, Bamshad MJ, Tracy RP, Cupples LA, Rader DJ, Reilly MP, Spertus JA, Cresci S, Hartiala J, Tang WH, Hazen SL, Allayee H, Reiner AP, Carlson CS, Kooperberg C, Jackson RD, Boerwinkle E, Lander ES,

- Schwartz SM, Siscovick DS, McPherson R, Tybjaerg-Hansen A, Abecasis GR, Watkins H, Nickerson DA, Ardissino D, Sunyaev SR, O'Donnell CJ, Altshuler D, Gabriel S, Kathiresan S. (including Dozor AJ). Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction. *Nature*. 2015 Feb 5; 518(7537):102-6. PMID: 25487149.
100. Smith LJ, Kalhan R, Wise RA, Sugar EA, Lima JJ, Irvin CG, Dozor AJ, Holbrook JT; American Lung Association Asthma Clinical Research Centers. Effect of a soy isoflavone supplement on lung function and clinical outcomes in patients with poorly controlled asthma: a randomized clinical trial. *JAMA*. 2015 May 26; 313(20):2033-43. PMID: 26010632.
 101. Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X, Cipolli M, Colombo C, Davies JC, De Boeck K, Flume PA, Konstan MW, McColley SA, McCoy K, McKone EF, Munck A, Ratjen F, Rowe SM, Waltz D, Boyle MP; TRAFFIC Study Group; TRANSPORT Study Group (including Dozor AJ). Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. *N Engl J Med*. 2015 Jul 16;373(3):220-31. PMID: 25981758.
 102. Auer PL, Nalls M, Meschia JF, Worrall BB, Longstreth WT Jr, Seshadri S, Kooperberg C, Burger KM, Carlson CS, Carty CL, Chen WM, Cupples LA, DeStefano AL, Fornage M, Hardy J, Hsu L, Jackson RD, Jarvik GP, Kim DS, Lakshminarayanan K, Lange LA, Manichaikul A, Quinlan AR, Singleton AB, Thornton TA, Nickerson DA, Peters U, Rich SS; National Heart, Lung, and Blood Institute Exome Sequencing Project. Rare and Coding Region Genetic Variants Associated with Risk of Ischemic Stroke: The NHLBI Exome Sequence Project (including Dozor AJ). *JAMA Neurol*. 2015 Jul;72(7):781-8. PMID: 25961151
 103. Kay DM, Langfelder-Schwind E, DeCelle-Germana J, Sharp JK, Maloney B, Tavakoli NP, Saavedra-Matiz CA, Krein LM, Caggana M, Kier C; New York State Cystic Fibrosis Newborn Screening Consortium (including Dozor AJ). Utility of a very high IRT/No mutation referral category in cystic fibrosis newborn screening. *Pediatr Pulmonol*. 2015 Aug; 50(8):771-80. PMID: 6098992.
 104. Sanders DB, Emerson J, Ren CL, Schechter MS, Gibson RL, Morgan W, Rosenfeld M; EPIC Study Group (including Dozor AJ). Early Childhood Risk Factors for Decreased FEV1 at Age Six to Seven Years in Young Children with Cystic Fibrosis. *Ann Am Thorac Soc*. 2015 Aug;12(8):1170-6. PMID: 26288390
 105. Morgan WJ, VanDevanter DR, Pasta DJ, Foreman AJ, Wagener JS, Konstan MW; Scientific Advisory Group; Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Forced Expiratory Volume in 1 Second Variability Helps Identify Patients with Cystic Fibrosis at Risk of Greater Loss of Lung Function. *J Pediatr*. 2016 Feb; 169:116-121. PMID: 26388208
 106. Hughes EE, Stevens CF, Saavedra-Matiz CA, Tavakoli NP, Krein LM, Parker A, Zhang Z, Maloney B, Vogel B, DeCelle-Germana J, Kier C, Anbar RD, Berdella MN, Comber PG, Dozor AJ, Goetz DM, Guida L Jr, Kattan M, Ting A, Voter KZ; New York State Cystic Fibrosis Newborn Screening Consortium, van Roey P, Caggana M, Kay DM. Clinical Sensitivity of Cystic Fibrosis Mutation Panels in a Diverse Population. *Hum Mutat*. 2016 Feb; 37 (2): 201.8. PMID: 26538069
 107. Majzner R, Sandoval C, Dozor AJ, Jin Z, van de Ven C, Dalal R, Morris E, Harrison L, Wolownik K, Fabricatore S, Baxter-Lowe, Cairo MS. Pulmonary function after hematopoietic stem cell transplantation is significantly better in pediatric recipients following reduced toxicity compared with myeloablative conditioning. *Bone Marrow Transplant*. 2016 June 20;51:1530-1532. PMID: 27322849
 108. Holbrook JT, Sugar EA, Brown RH, Drye LT, Irvin CG, Schwartz AR, Tepper RS, Wise RA, Yasin RZ, Busk MF; American Lung Association–Airways Clinical Research Centers (including Dozor AJ). Effect of CPAP on Airways Reactivity in Asthma: A Randomized Sham-Controlled Clinical Trial. *Ann Am Thorac Soc*. 2016 Jul 11. PMID: 27398992
 109. Broglie L, Talano J, Moore T, Shenoy S, Mahanti H, Morris E, Horowitz T, Fabricatore S, Abikoff C, Dozor A, Cairo M. Stabilization of Pulmonary Function in Pediatric and Young Adult Sickle Cell Disease (SCD) Recipients Undergoing Myelo-Immunosuppressive (MIC) and Familial Haploidentical (FHI) Transplantation Enriched CD34 Selection and T-Cell Add-Back. In *Pediatric Blood & Cancer* 2017 Jun 1 (Vol. 64, pp. S99-S99). 111 River Street, Hoboken, NJ USA: Wiley.

110. Julie-An Talano, Theodore B Moore, Carolyn A. Keever-Taylor, Shalini Shenoy, Mark C. Walters, Susan K Parsons, Allen J Dozor, Deborah Friedman, Qiuhu Shi, Suzanne Braniecki, Brenda J. Grossman, Rona Singer Weinberg, Elliott Vichinsky, Yaya Chu, Erin Morris, Sandra Fabricatore, Janet Ayello, Lee Ann Baxter-Lowe and Mitchell S. Cairo. Promising Results at 1 Year Follow-up Following Familial Haploidentical (FHI) T-Cell Depleted (TCD) with CD34 Enrichment and T-Cell (CD3) Addback Allogeneic Stem Cell Transplantation in Patients with High-Risk Sickle Cell Disease (SCD) (IND 14359). *Blood* 2017 130:4602
111. Mink R, Schwartz A, Carraccio C, High P, Dammann C, McGann KA, Kesselheim J, Herman B; Steering Committee of the Subspecialty Pediatrics Investigator Network (including Dozor AJ). Creating the Subspecialty Pediatrics Investigator Network. *J Pediatr*. 2018 Jan;192:3-4. e2. PMID: 29246355
112. Caylan E, Weinblatt E, Welter J, Dozor A, Wang G, Nolan SM. Comparison of the severity of respiratory disease in children testing positive for enterovirus D68 and human rhinovirus. *J Pediatr* 2018; 197:147-153. PMID: 29655864
113. Krishnan S, Dozor AJ, Bacharier L, Lang JE, Irvin CG, Kaminsky D, Farber HJ, Gerald L, Brown M, Holbrook JT, Wise RA, Ryu J, Bose S, Yasin R, Saams J, Henderson RJ, Teague WG, American Lung Association Airway Clinical Research Centers (ALA-ACRC) Network. Clinical characterization of children with resistant airflow obstruction, a multicenter study. *J Asthma*. 2019 Jun;56(6):611-617. PMID: 29771599.
114. Rosenthal EA, Shirts BH, Amendola LM, Horike-Pyne M, Robertson PD, Hisama FM, Bennett RL, Dorschner MO, Nickerson DA, Stanaway IB, Nassir R, Vickers KT, Li C, Grady WM, Peters U, Jarvik GP; NHLBI GO Exome Sequencing Project. (including Dozor AJ). Rare loss of function variants in candidate genes and risk of colorectal cancer. *Hum Genet*. 2018; 137(10):795-806. PMID: 30267214
115. Galvez M, Collins G, Amler RW, Dozor A, Kaplan-Liss E, Forman J, Laraque-Arena D, Lawrence R, Miller R, Miller K, Sheffield P, Zajac L, Landrigan PJ. Building New York State Centers of Excellence in Children's Environmental Health: A Replicable Model in a Time of Uncertainty. *Am J Public Health*. 2019 Jan; 109(1):108-112. PMID: 30496005.
116. Krishnan S, Rohman A, Welter J, Dozor AJ. Relationship between health literacy in parents and asthma control in their children: a prospective study in a diverse suburban population. *Pediatric Allergy, Immunology, and Pulmonology* 2018; 31 (4) 221- 225.
117. Krishnan S, Iannotti V, Welter J, Gallagher MM, Ndjatou T, Dozor AJ. Bronchodilators, Antibiotics, and Oral Corticosteroids Use in Primary Care for Children with Cough. *Glob Pediatr Health*. 2019 Feb 25;6: PMID: 30828592
118. Kern-Goldberger AS, Hill-Ricciuti AC, Zhou JJ, Savant AP, Rugg L, Dozor AJ, Welter J, Saiman L, Quittell LM. Perceptions of safety monitoring in CF clinical studies and potential impact on future study participation. *J Cyst Fibros* 2019; July; 18 (4): 530-535. PMID: 31151855
119. Kim C, delaRiva-Velasco E, Budhram A, Farri F, Krich D, Nolan SS, Gjonaj S, Paul L, Dozor AJ, Welter JJ. Incidence and prevalence of common respiratory pathogens before and after implementation of the Cystic Fibrosis Foundation Infection Prevention and Control Guideline. *Journal of Infection Prevention*, Sept 2019: PMID 32030098.
120. Venkat AR, Prish C, Brown A, Dozor AJ. Left to their own devices: A glance into the byzantine world of obtaining asthma spacing devices. *Clin Pediatr (Phila)* 2020; Jan 20. PMID: 21958980
121. Chmiel JF, Flume P, Downey DG, Dozor AJ, Colombo C, Mazurek H, Sapiejka E, Rachel M, Constantine S, Conley B, Dgetluck N, Dinh Q, White B, Elborn JS; Lenabasum JBT101-CF-001 Study Group. Safety and efficacy of lenabasum in a phase 2 randomized, placebo-controlled trial in adults with cystic fibrosis. *J Cyst Fibros*. 2020 Sep 30: S1569-1993(20)30873-0. PMID: 33011099
122. Krich D, Dozor AJ, Krishnan S. Airway Closing Index in School-age Children during Exercise Bronchoprovocation. *J Asthma*. 2020 Nov 13:1-8. PMID: 33187460
123. Friedman D, Dozor AJ, Milner J, D'Souza M, Talano JA, Moore TB, Shenoy S, Shi Q, Walters MC, Vichinsky E, Parsons SK, Braniecki S, Moorthy CR, Ayello J, Flower A, Morris E, Mahanti H, Fabricatore S, Klejmunt L, van de Ven C, Baxter-Lowe LA, Cairo MS. Stable to improved cardiac and pulmonary function in children with high-risk sickle cell disease following haploidentical stem cell transplantation. *Bone Marrow Transplant*. 2021 Sep;56(9): 2221-2230. PMID: 33958740.
124. Reyfman PA, Sugar E, Hazucha H, Hixon J, Reynolds C, Bose S, Dransfield MT, Han MK, Estepar RSJ, Rice MB, Washko GR, Carnethon M, Kalhan R; American Lung Association Airways Clinical Research Network; American Lung Association Airways Clinical Research Network (Including Dozor AJ). Study protocol for a national cohort of adults focused on

respiratory health: the American Lung Association Lung Health Cohort (ALA-LHC) Study. *BMJ Open*. 2021 Jul 5;11(7):e053342. PMID: 34226239.

125. Welter J, Lennox A, Krishnan S, Kim C, Krishnan S, Thompson H, Mcallister E, Huang K, Nwaedozie K, Dozor A. The relationship between weight and pulmonary outcomes in overweight and obese people with cystic fibrosis. *Authorea Preprints*. 2021 Aug 4.
126. Schluger NW, Dozor AJ, Jung YEG. Rethinking the Race Adjustment in Pulmonary Function Testing. *Ann Am Thorac Soc*. 2021 Nov 16. *Annals ATS*. Epub ahead of print. PMID: 34784493.
127. Goss CH, Heltshe SL, West NE, Skalland M, Sanders DB, Jain R, Barto TL, Fogarty B, Marshall BC, VanDevanter DR, Flume PA; STOP2 Investigators (including Dozor AJ). A Randomized Clinical Trial of Antimicrobial Duration for Cystic Fibrosis Pulmonary Exacerbation Treatment. *Am J Respir Crit Care Med*. 2021 Dec 1;204(11):1295-1305. PMID: 34469706.

BOOKS / BOOK CHAPTERS / EDITORIAL POSITIONS / BOOK REVIEWS:

Dozor AJ. Disorders of the Respiratory Tract, in *Nutritional Care of Children with Chronic Disorders*. Schwarz S., Boyle J., eds. Futura Publishing Co. In Press.

Editorial Advisory Board, *Asthma Management*. 1992-Present. Pollowitz J., Sherter C., eds. Liebert, Inc. Publisher, New York, New York.

Pediatric representative, National Consensus Conference: Guidelines for the use of nebulizers in the home and at domiciliary sites, sponsored by the Health Care Financing

Administration (HCFA) and the National Association for Medical Director of Respiratory Care (NAMDRC). June, 1995; 22-23. Dozor AJ. Book review: *Handbook of Pediatric Intensive Care*, 2nd ed. edited by MC Rogers and MA Helfaer, in *Pediatric Pulmonology* 1996; 21:262.

Dozor AJ. Editor, *Primary Pediatric Pulmonology*, New York, Futura Publishing Co. November 2000.

Dozor AJ, Kelly K. *Allergies and Asthma Action Plan for Kids: A Complete Program to Help Your Child Live a Full and Active Life*. New York, Simon & Schuster, April, 2004.

Aljundi E, Dozor AJ. Book Review: *Lung Disease in Early Infancy*, edited by Richard D. Bland and Jacqueline J. Coalson, in *Pediatric Pulmonology* 2004; 38:91-92.

Stokes D and Dozor AJ. Co Editors, *Pediatric Pulmonology, Asthma, and Sleep Medicine: A Quick Reference Guide*: American Academy of Pediatrics April 2018.

ABSTRACTS AND NATIONAL PRESENTATIONS:

1. Dozor AJ, McLaughlin FJ, Wohl MEB: Cold Air Challenge in Asthmatic Children. *Pediatric Research* 1982: (p112); 349A (Oral presentation at Society of Pediatric Research meeting, 1982).
2. McLaughlin FJ, Dozor AJ, Wohl MEB. Comparison of Airway Reactivity Induced by Isocapnic Hyperventilation with Cold Air in Asthmatic Children and Adults, *Am Rev Respir Dis* 1984; 129: A221.
3. Geggel RL, Dozor AJ, Fyler DC, Reid LM. Effect of Vasodilators at Rest and During Exercise in Young Adults with Cystic Fibrosis and Cor Pulmonale, *Am Rev Respir Dis* 1984; 129: A61 (Oral presentation at the American Thoracic Society, 1984).
4. Dozor AJ, Denning CR. Differences in Respiratory Heat and Water Loss Between Patients with Cystic Fibrosis and Healthy Volunteers. *Am Rev Respir Dis* 1985; 131:A239 (Oral presentation at the American Thoracic Society, 1985).
5. Dozor AJ, Denning CR. Respiratory Heat and Water Exchange in Healthy Volunteers: The Effects of Changes in Respiratory Rate, Tidal Volume and Minute Ventilation. *Am Rev Respir Dis* 1985; 131:A306 (Oral presentation at the American Thoracic Society, 1985).
6. Schwarz SM, Berezin S, Dozor AJ, Glassman MS, Newman LJ. Gastroesophageal Reflux (GER) in

Infants with Apparent Life-Threatening Events (ALTE). *Pediatric Research* 1988; 23(4):312A (Oral presentation at the Society for Pediatric Research, 1988).

7. See CC, Newman LJ, Glassman MS, Schwarz SM, Berezin S, Dozor AJ, Thek KM, Teemley EK. Gastroesophageal Reflux (GER) Induced Hypoxemia in Infants with Apparent Life-Threatening Events (ALTE). *Pediatric Research* 1988; 23(4):312A (Oral presentation at the Society for Pediatric Research, 1988).
8. Tonzola D, Dozor AJ, Keisari R, Leistner HL: Recurrent Lower Respiratory Tract Disease in Infants Presenting with Laryngotracheomalacia. *Am Rev Resp Dis* 1990, 141(4):901 (Poster at the American Thoracic Society, 1990).
9. Schroeder, SA and Dozor AJ: Pneumothorax in Children with AIDS. *Pediatric Research* (1993) 33:387.
10. Lowenfels, AB, Neglia, JD, Dozor AJ, Fitzsimmons S: Cystic Fibrosis and the Risk of Cancer. *Pediatric Pulmonology* 1990 (9):344. (Poster at the North American Cystic Fibrosis Conference, 1993).
11. Fuchs HJ and the Pulmozyme study group (Dozor AJ), Phase III trial of Dnase in patients with CF. *Pediatric Pulmonology* 1993 (supp 9): p. 152-153. Presented at the North American Cystic Fibrosis Conference, 1993.
12. Wilmott RW, et al, (Dozor AJ). Phase II trial of Dnase in CF patients hospitalized for pulmonary exacerbations. *Pediatric Pulmonology* 1993; (supp 9): p.154. Presented at the North American Cystic Fibrosis Conference, 1993.
13. Ramsey B, et al, (Dozor AJ). Multicenter trial of three different nebulizer systems for delivery of Dnase in CF. *Pediatric Pulmonology* 1993; (supp 9): p.155. Presented at the North American Cystic Fibrosis Conference, 1993 and published as a consensus conference in *Pediatric Pulmonology* 1994; 17(6): p. 404-408.
14. Rosenstein BJ, et al, (Dozor AJ). Multicenter open-label treatment protocol to provide DNase to patients with CF. *Pediatric Pulmonology* 1994; (supp 10): p. 115. Presented at the North American Cystic Fibrosis Conference, 1994.
15. Neglia and the Cystic Fibrosis and Cancer study group. (Lowenfels A, Dozor AJ). Cancer risk amongst CF patients in the U.S., Canada and Europe. *Pediatric Pulmonology* 1994; suppl 10: 172-173 and *Pediatric Pulmonology* 1995; suppl 12: 92. Oral and poster presentations at 1993, 1994 and 1995 North American Cystic Fibrosis Conferences.
16. Lowenthal DB, Loutsch EM, and Dozor AJ. Panic Attack in adolescent asthmatics. *Chest* 1995;108:3:216. Poster presentation at the 1995 American College of Chest Physicians.
17. Boyer J, Amin N, Taddonio R, and Dozor AJ. Reversible airway obstruction in children with idiopathic scoliosis. *Chest* 1995; 108:3: 148S. Poster presentation at the 1995 American College of Chest Physicians.
18. Krishnan S, Amin N, Stewart J, Dozor AJ. Relationship between mean frontal p wave axis and hyperinflation in children. *Am J Respir Crit Care Med* 1996, vol 153(4): A560. Poster presentation at the 1996 American Thoracic Society.
19. Schroeder SA, Roslansky P, Warren HS, Dozor AJ. Detection and localization of endotoxin in the lungs. *Am J Respir Crit Care Med* 1996, vol 153(4). A591. Poster presentation at the 1996 American Thoracic Society.
20. Schroeder SA, Davidson C, Cheli C, Amin N, Dozor AJ and Gurtner GH. Arachidonic acid metabolism in the bronchial epithelium of patients with cystic fibrosis. *Am J Respir Crit Care Med* 1996, vol 153(4): A777. Poster presentation at the 1996 American Thoracic Society.
21. Gjonaj ST, Lowenthal DB, Dozor AJ. Nebulized lidocaine administered to infants and children undergoing flexible bronchoscopy. *Am J Resp Crit Care Med* 1997, vol 155 (4): A710. Poster presentation at the 1997 Annual Meeting of the American Thoracic Society.
22. Krishnan S, Amin N, Dozor AJ. Inadequacy of peak flow in detecting hyperinflation in childhood asthma. *Am J Resp Crit Care Med* 1997, vol 155 (4): A970. Poster presentation at the 1997 Annual Meeting of the American Thoracic Society.
23. Colin AA, and the Epidemiologic study of Cystic Fibrosis (ESCF) Scientific Advisory Group (Dozor, AJ) Antibiotic

- prophylaxis in Cystic Fibrosis: Results of a survey in the northeastern United States. *Am J Resp Crit Care Med* 1997, vol 155(4): A640. Poster presentation at the 1997 Annual Meeting of the American Thoracic Society.
24. Stringel G, Amin N, Dozor AJ. Video assisted thoracoscopy in the management of recurrent spontaneous pneumothorax in children. Annual Meeting of the Society of Laparoendoscopic surgeons, December 1997.
 25. Stringel G, Amin N, Sadeghi H, Dozor AJ. Unsuspected foreign body aspiration and asthma. Annual Meeting of the Society of Laparoendoscopic surgeons, December 1997.
 26. Sadeghi H, Lowenthal DB, Dozor AJ. Difference in pulmonary function between Children with bronchopulmonary dysplasia and asthma. *Am J Resp Crit Care Med* 1998 vol 157(3): A375. Poster presentation at the 1998 Annual Meeting of the American Thoracic Society.
 27. Sadeghi H, Dozor AJ. Respiratory heat and water losses in cystic fibrosis. *Am J Resp Crit Care Med* 1999 vol 159(3): A683. Poster presentation at the 1999 Annual Meeting of the American Thoracic Society.
 28. Akanli L, Dozor AJ. Plasma and red blood cell zinc levels in cystic fibrosis. *Pediatric Pulmonology* 1999; suppl 19: 299. Poster presentation at the 1999 North American Cystic Fibrosis Conference.
 29. Amin N, Jalou HE, Dozor AJ. Serum uric acid as a marker for nocturnal hypoxemia in patients with cystic fibrosis. *Am J Resp Crit Care Med* 2002 vol 165(8): A286. Poster Presentation at the 2002 Annual Meeting of the American Thoracic Society.
 30. Assefa D, Amin N, Dozor AJ. Effect of deep inspiration on airway caliber in children with asthma. *Am J Resp Crit Care Med* 2002 vol 165 (8): A779. Poster presentation at the 2002 Annual Meeting of the American Thoracic Society.
 31. Jovanovic M, Rashid AI, Amin N, Dozor AJ. Long-term outcome of childhood asthma: Does chronic anti-inflammatory therapy in early childhood matter? *Chest* 2002: Poster presentation at the 2002 Annual Meeting of the American College of Chest Physicians.
 32. Assefa D, Amin N, Stringel G, Dozor AJ. Lateral Decubitus Films in the Diagnosis of Foreign body aspiration in younger children. Are they really necessary? *Am J Respir Crit Care Med* 2004; 167(7): A388. Poster presentation at the 2003 Annual Meeting of the American Thoracic Society.
 33. Welter JJ, Assefa D, Godi I, Strassberg SS, Amin N, Dozor A, Parton LA. Cytokine single nucleotide polymorphisms (SNPs) and disease severity in infants with respiratory syncytial virus (RSV) bronchiolitis. *Am J Respir Crit Care Med* 2004;169(7): A141. Poster Presentation at the 2004 Annual Meeting of the American Thoracic Society.
 34. Assefa D, Doshi N, Godi I, Amin N, Dozor AJ, Parton LA. A comparison of cytokine response in preterm (PT) and full term (FT) infants with respiratory syncytial virus (RSV) bronchiolitis. *Am J Respir Crit Care Med* 2004: 169 (7): A141. Poster Presentation at the 2004 Annual Meeting of the American Thoracic Society.
 35. Welter JJ, Assefa D, Godi I, Strassberg SS, Amin N, Dozor A, Parton LA. Interleukin 8 (IL-8) Single Nucleotide Polymorphisms (SNPs) in Infants with Respiratory Syncytial Virus (RSV) Bronchiolitis: A Comparison of Full Term (FT) and Preterm (PT) Infants. *Pediatric Research* 2005. Poster presentation at the Society of Pediatric Research, May 2005.
 36. Krishnan S, Dozor AJ, Griffin R, Amin N. Isovolumetric FEV_{25-75%} in childhood asthma. *Am J Respir Crit Care Med* 2005: volume 2: A185. Poster Presentation at the 2005 Annual Meeting of the American Thoracic Society, May 2005.
 37. Welter JJ, Assefa D, Godi I, Strassberg SS, Amin N, Dozor AJ, Parton LA. Interleukin 8 (IL-8) airway levels and IL-8 single nucleotide polymorphisms (SNP) in infants with respiratory syncytial virus (RSV) bronchiolitis. *Am J Respir Crit Care Med* 2005: volume 2: A188. Poster Presentation at the 2005 Annual Meeting of the American Thoracic Society, May 2005.
 38. Welter JJ, Munoz J, Dozor AJ. Methicillin resistant staphylococcus aureus (MRSA) susceptibility patterns in patients with cystic fibrosis. *Am J Respir Crit Care Med* 2005: volume 2: A119. Poster Presentation at the 2005 Annual Meeting of the American Thoracic Society, May 2005.

39. Krishnan S, Diaz J, Cooper N, Chaudhary KU, Dozor AJ. Influence of barometric pressure on lung function in children with asthma. *Am J Respir Crit Care Med* 2005; volume 2: A119. Poster Presentation at the 2005 Annual Meeting of the American Thoracic Society, May 2005.
40. Krishnan S, Amin N, Dozor, A. FEF25-75/FVC as a measure of dysanapsis in asthmatic children born prematurely. *Am J Respir Crit Care Med* 2006. volume 2: A122. Oral presentation in the symposium on "Lung Function Testing in Infants and Young Children" at the 2006 Annual Meeting of the American Thoracic Society, May 2006.
41. Jean Baptiste JE, Amin N, Dozor AJ. Spirometry with and without Noseclips in Children. Is there a Difference? *Am J Respir Crit Care Med* 2007; 175: A490. Poster presentation at the 2007 Annual Meeting of the American Thoracic Society, May 2007.
42. Banquet A, Amin N, Welter J, Dozor AJ, Ali N, Pham C, Kaoi E, Patton L. B2-adrenergic receptor polymorphisms and response to albuterol in infants with RSV bronchiolitis. *Am J Respir Crit Care Med* 2007; 175: A760. Slide presentation at the 2007 Annual Meeting of the American Thoracic Society, May 2007.
43. Khullar M, Krishnan S, Chaudhary S, Dozor AJ. Variability of spirometry including FEF25_75/FVC in Cystic Fibrosis. *Am J Respir Crit Care Med* 2007; 175:A844. Slide presentation at the 2007 Annual Meeting of the American Thoracic Society, May 2007.
44. Krishnan S, Chaudhary KU, Dozor AJ. Clinical significance of FEF25-75/FVC ratio in Children with asthma. *Am J Respir Crit Care Med* 2007; 175:A725. Poster presentation at the 2007 Annual Meeting of the American Thoracic Society, May 2007.
45. Gregoire-Bottex MM, Amin N, Banquet A, Mitchell M, Dozor AJ. Carboxyhemoglobin concentration in infants with bronchopulmonary dysplasia. *Am J Respir Crit Care Med* 2008; 177: A447. Poster presentation at the 2008 Annual Meeting of the American Thoracic Society, May 2008.
46. Khullar M, Hingorani S, Welter JJ, Dozor AJ. Relationship between serum vitamin D levels and pseudomonas aeruginosa in patients with cystic fibrosis. *Am J Respir Crit Care Med* 2008; 177: A455. Poster presentation at the 2008 Annual Meeting of the American Thoracic Society, May 2008.
47. Newport SA, Amin N, Aguero-Rosenfeld M, Dozor AJ. Expired breath condensate pH in cystic fibrosis and response to treatment of acute pulmonary exacerbations. *Am J Respir Crit Care Med* 2008; 177: A460. Poster presentation at the 2008 Annual Meeting of the American Thoracic Society, May 2008.
48. Shah AC, Welter JJ, Smyth DD, Robinson DA, Dozor AJ. Prevalence of Pantone-Valentine Leukocidin (PVL) in *S. aureus* isolates from patients with cystic fibrosis. *Am J Respir Crit Care Med* 2008; 177: A461. Poster presentation at the 2008 Annual Meeting of the American Thoracic Society, May 2008.
49. Stout JW, Smith K, Zhou C, Solomon C, Dozor A, Mangione-Smith R. Learning from a Distance: A cluster randomized trial of a program to improve asthma care through interactive, online spirometry training and feedback. 2010 IPCRG World Conference, Toronto, June 2010.
50. DeLaRiva-Velasco E, Siegel S, Dozor AJ. Case Report: Four-year old with recurrent sinopulmonary infections. *Am J Respir Crit Care Med* 2010; A6213. Poster presentation at the 2010 Annual Meeting of the American Thoracic Society, May, 2010.
51. Khullar M, Welter J, Dozor, AJ. Relationship between sputum cathelicidin and serum 25-OH vitamin D in cystic fibrosis. *Am J Respir Crit Care Med* 2010; A6263. Poster presentation at the 2010 Annual Meeting of the American Thoracic Society, May 2010.
52. Valsamis C, Dozor AJ. Low-level environmental tobacco smoke exposure and lung function in asthmatic children three to six years of age. *Am J Respir Crit Care Med* 2011; A1883. Poster presentation at the 2011 Annual Meeting of the American Thoracic Society, May 2011.
53. DeLaRiva-Velasco E, Krishnan S, Dozor AJ. Biomarkers of airway inflammation in asthmatic children on inhaled corticosteroid therapy exposed to low levels of environmental tobacco smoke. *Am J Respir Crit Care Med* 2011; 183: A5462. Poster presentation at the 2011 Annual Meeting of the American Thoracic Society, May 2011.

54. Dozor AJ, Stout JW, Smith K, Zhou C, Solomon S, Mangione-Smith R. Learning from a distance: a cluster randomized trial of a program to improve asthma care through interactive, online spirometry training and feedback. *Am J Respir Crit Care Med* 2011; 183: A5473. A. Poster presentation at the 2011 Annual Meeting of the American Thoracic Society, May 2011.
55. Dozor AJ, Smith K, Stout JW. A novel approach to interactive online training and feedback. *Am J Respir Crit Care Med* 2011; 183: A5589. A Poster presentation at the 2011 Annual Meeting of the American Thoracic Society, May 2011.
56. Scharbach M, Welter J, Munoz J and Dozor AJ. Morbidity and mortality associated with 2009 H1N1 compared with other influenza illnesses in children. *Am J Respir Crit Care Med* 2011; 183: A6283. Poster presentation at the 2011 Annual Meeting of the American Thoracic Society, May, 2011.
57. Gill R, Krishnan S, Dozor A. Low-level environmental tobacco smoke exposure and inflammatory biomarkers in children with asthma. Presented at the 2011 American Thoracic Society Annual Conference, San Francisco. .
58. Cori Abikoff, Julie-An Talano, Carolyn Keever-Taylor, Mark Walters, Shalini Shenoy, Theodore B. Moore, Susan K. Parsons, Allen J. Dozor, Deborah Friedman, Ramanamoorthy Chitti, Qihui Shi, Brenda Grossman, Rona Weinberg, Erin Morris, Phyllis Brand, Sandra Fabricatore, Olga Militano, Janet Ayello, Mildred Semidei-Pomales, Lee Ann Baxter-Lowe, Mitchell S. Cairo. Differences in pulmonary function between “coughers” and “wheezers” with childhood asthma using impulse oscillometry in lung function between coughers and wheezers. Poster presentation at the 2013 Annual Meeting of the American Thoracic Society, May 2013, Philadelphia. Primary investigator. *Am J Respir Crit Care Med* 2013; A4203.
59. Banquet A, Krishnan S, Ansehl A, Kim YC, Archer Smith H, Dozor AJ. Primary care asthma preceptorship program (PCAP): A novel approach to address disparities in the care of children with asthma and promote best practices by community-based providers. *Am J Respir Crit Care Med* 2013; A4203. Poster presentation at the 2013 Annual Meeting of the American Thoracic Society,
60. Krishnan S, Cromar K, Thurston GD, Dozor AJ. Ozone, obesity and lung function in children with asthma. Oral presentation in symposium on Environment and Asthma at the 2013 American Thoracic Society Annual Conference, Philadelphia. *Am J Respir Crit Care Med* 2013; A2523.
61. Dozor AJ, Krishnan S, Kim YC, Banquet A, Ansehl A, Amler RW. Developing a regional children’s environmental health center – successes and challenges. Presented at the 7th International conference on children’s Environmental Health and Safety (INCHESS), Jerusalem, Israel, November 20 – 22, 2013. Abikoff C, et al (including Dozor AJ).
62. Treatment of High-Risk Sickle Cell Disease (SCD) with Familial Haploidentical (FHI) T-Cell Depleted (TCD) Stem Cell Transplantation with T-Cell Addback (IND). *Biology of Blood and Marrow Transplantation*, 2015-02-01, Volume 21, Issue 2, Pages S90-S9.
63. Pandey S, Krishnan S, Traeger N, Prashad P, Parton LA, Dozor AJ. Urinary Bnp And Nt-Probnp As Biomarkers of Obstructive Sleep Apnea Syndrome In Children. *Am J Respir Crit Care Med* 2015, Poster presentation at the 2015 Annual Meeting of the American Thoracic Society, May 2015.
64. Pandey S, Krishnan S, Traeger N, Prashad P, Parton LA, Dozor AJ. Association Between Environmental Tobacco Smoke Exposure And Obstructive Sleep Apnea Syndrome In Children. *Am J Respir Crit Care Med* 2015, Poster presentation at the 2015 Annual Meeting of the American Thoracic Society, May 2015.
65. Krishnan S, Dozor AJ. Obesity And Pulmonary Function In Preschool Children With Asthma. *Am J Respir Crit Care Med* 2015, Poster presentation at the 2015 Annual Meeting of the American Thoracic Society, May 2015.
66. Krishnan S, Dozor AJ. Fixed Airflow Obstruction In Children With Physician-Diagnosed Asthma. *Am J Respir Crit Care Med* 2015, Poster presentation at the 2015 Annual Meeting of the American Thoracic Society, May 2015.
67. Krishnan S, Dozor AJ. Ambient air pollution and risk of hospitalization for children presenting to the emergency department with an acute asthma exacerbation. *Am J Respir Crit Care Med* 2015, Poster presentation at the 2015 Annual Meeting of the American Thoracic Society, May 2015.
68. Krishnan S, Dozor AJ, et al. Resistant Airway Obstruction in Children. *Am J Respir Crit Care Med* 2016; poster presentation at the 2016 annual meeting of the American Thoracic Society, May 2016

69. Krishnan S, Hettiaracchi D, Scharbach M, Dozor AJ. Obesity and pulmonary function in school-age children with asthma. *Am J Respir Crit Care Med* 2016; poster presentation at the 2016 annual meeting of the American Thoracic Society, May, 2016
70. Krishnan S, Rohman A, Dozor AJ. Relationship between health literacy and numeracy of parents and asthma control in their children. *Am J Respir Crit Care Med* 2016; poster presentation at the 2016 annual meeting of the American Thoracic Society, May 2016
71. Liang T, Kumar M, Miller C, Patel D, Dozor AJ, Krishnan S. Prescribing controller therapy for asthma upon discharge from a pediatric emergency department: a quality improvement initiative. *Am J Respir Crit Care Med* 2016; poster presentation at the 2016 annual meeting of the American Thoracic Society, May 2016
72. Kumar M, Liang T, Patel D, Dozor AJ, Krishnan S. Controller therapy in children with asthma presenting to the pediatric emergency department. *Am J Respir Crit Care Med* 2016; poster presentation at the 2016 annual meeting of the American Thoracic Society, May 2016
73. Kim C, Welter J, delaRiva-Velasco E, Nolan S, Paul L, Dozor AJ. The relationship between implementation of the 2013 CF Foundation Infection control guidelines on the incidence and prevalence of pathogenic bacteria in respiratory cultures from patients with cystic fibrosis. Poster Presentation at the 2016 North American Cystic Fibrosis Foundation Annual Conference, October 2016.
74. Talano, J-A., Abikoff, C., Keever-Taylor, C., Walters, M.C., Shenoy, S., Moore, T.B., Parsons, S.K., Dozor, A.J., Friedman, D., Shi, Q., Braniecki, S., Grossman, B., Weinberg, R.S., Morris, E., Brand, P., Fabricatore, S., Ayello, J., Semidei-Pomales, M., Baxter-Lowe, L.A., and Cairo, M.S. Familial haploidentical (FHI) T-cell depleted (TCD) with T-cell addback stem cell transplantation for patients with high-risk sickle cell disease. Accepted, American Society of Blood and Marrow Transplantation, 2017; #442. ASBMT, Orlando, FL, February 2017.
75. Krishnan S, Dozor AJ, Holbrook J, Wise RA, Bacharier LB, Kaminsky DA, Irvin CG, Farber HJ, Lang JE, Shade D, Green D, Gerald LB, Ryu J, Brown MA, Bose S, Saams J, Yasin R, Teague WG. Resistant Airway Obstruction In Children. Oral presentation in symposium sponsored by the American Lung Association Airways Clinical Research Centers network at the 2017 American Thoracic Society Annual conference, San Francisco.
76. Krishnan S, Ansehl A, Lopez-Novillo A, Dozor AJ. Parental Self-Reported Environmental Exposures in over 9000 children with Respiratory Illness. *Am J Respir Crit Care Med* 195; 2017: A4832.
77. Broglie L, Talano J, Moore T, Shenoy S, Mahanti H, Morris E, Horowitz T, Fabricatore S, Abikoff C, Dozor AJ, and Cairo MS. Stabilization of pulmonary function in pediatric and young adult sickle cell disease recipients undergoing myelo-immunosuppressive and familial haploidentical transplantation enriched CD34 selection and T-cell add-back. Presented, Pediatric Blood and Marrow Transplantation, April 2017; *Pediatric Blood & Cancer* 2017: e26591, #1017.
78. Krishnan S, Ansehl A, Lopez-Novillo A, Dozor AJ. Influence of Primary Residence: Urban, Rural or Suburban, on Parental Self-Reported Environmental Exposures in over 9000 children with Respiratory Illness. *Am J Respir Crit Care Med* 195; 2017: A4800.
79. Lin NY, Krishnan S, Deazambuja K, Tun B, Dozor AJ. Relationship Between Antibody Response to Pneumococcal Antigens and Atopy In Young Children With Recurrent Respiratory Disease. *Am J Respir Crit Care Med* 195; 2017: A1194.
80. Krishnan S, Dozor AJ. Inspiratory-Expiratory Differences in Respiratory System Reactance and Resistance As Measured By Forced Oscillometry In Children With Cystic Fibrosis And Asthma. *Am J Respir Crit Care Med* 195; 2017: A4124.
81. Flower A, Talano J, Moore T, Shenoy S, Broglie L, Mahanti H, Morris E, Fabricatore S, Dozor AJ, and Cairo MS. Stable pulmonary function after myeloimmunosuppressive conditions and familial haploidentical transplantation utilizing CD34+ enrichment and PBMC add back in children and young adults with high-risk sickle cell disease. Presented, Association of blood and Marrow Transplantation 2018, #300. *Biology of Blood and Marrow Transplantation*, March 2018; 24(3):DS222.
82. Cairo MS, Talano J, Moore TB, Keever-Taylor C, shenoy S, Walters MC, Parsons SK, Dozor AJ, Friedman D, Shi Q, Braniecki S, Grossman B, Weinberg RS, Vichinsky E, Chu Y, Morris E, Fabricatore S, Ayello J, and Baxter-Lower LA. Final results following familial haploidentical CD34 enriched and T-cell addback allogeneic stem cell transplanting in patients with high-risk sickle cell disease (IND 14359). Presented, European Society for Blood and Marrow Transplantation, 2018, #A-947-0026-0047.

83. Brown A, Budhram A, Zheng E, Prish C Boyer K, Dozor AJ, Krishnan S. Use of Personal Care Products in Children with Respiratory Illnesses. *Am J Respir Crit Care Med* 197; 2018: A3654.
84. Krich DA, Krishnan S, Harris KN, Arlievsky N, Dozor AJ. 11-Month-Old Infant with a Mediastinal Mass with Endobronchial Extension Presenting as Persistent Wheeze. *Am J Respir Crit Care Med* 197; 2018: A5600.
85. Caylan E, Dozor AJ, Parton LA, Krishnan S. Resistant Airflow Obstruction in Children with Asthma. *Am J Respir Crit Care Med* 197; 2018: A3932.
86. Siegel S, Budhram A, Kane R, Yu R, Dozor AJ, Krishnan AJ. Atopic Disease in Children with Eosinophilic Esophagitis. *Am J Respir Crit Care Med* 197; 2018: A1168.
87. Krich DA, Krishnan S, Dozor AJ. Airway Closing Index in Children During Exercise Bronchoprovocation. *Am J Respir Crit Care Med* 197; 2018: A7278.
88. Watson J, Flower A, Morris E, Fabricatore S, Friedman D, d'Souza M, Dozor AJ, and Cairo M. Long term pulmonary and cardiac effects of myeloimmunoablative conditioning following familial haploidentical allogeneic stem cell transplant (AlloSCT) in high-risk patients with sickle cell disease (SCD). Presented, Paul Wolff MD Pediatric Research Day, May, 2018
89. Cairo MS, Parsons SK, Braniecki S, Talano J-A, Moore TB, Shi Q, Keever-Taylor C, Weinberg RS, Grossman B, Dozor AJ, Friedman D, McKinstry RC, Verbsky J, Moorthy CR, Weidner RA, rodday AM, Ayello J, Semidei-Pomales M, Flower A, Chu Y, Morris E, Mahanti H, Fabricatore S, Militano O, Klejmont L, van de Ven C, Baxter-Lowe LA, Vichinsky E, Walters MC, and Shenoy S. Significantly improved long term health related quality of life (HRL) and neurocognition following familial haploidentical stem cell transplantations (HISCT) utilizing CD34 enrichment and mononuclear (CDs) addback in high risk patients with sickle cell disease (SCD). Accepted for presentation, American Society of Hematology (ASH), 2018, #162.
90. Ferguson KF, Khazaei Nejad S, Krich D, Gilani S, Gault C, Dozor AJ, S. Krishnan S. 17-Year-Old Male with a Pleural Effusion and Pulmonary Nodule *Am J Respir Crit Care Med* 2020;201: A7344.
91. Panacherry S, Krishnan S, Dozor AJ. Low Nasal Nitric Oxide in Children with Secondhand Tobacco Smoke Exposure - A Potential Confounder in Diagnosis of PCD. *Am J Respir Crit Care Med* 2020;201: A5327.
92. Pollack Y, McAllister E, Dozor AJ, Krishnan S. Ventilatory Non-homogeneity in Children with Bronchopulmonary Dysplasia. *Am J Respir Crit Care Med* 2020;201: A4675.
93. Krich D, Krishnan S, Welter J, Boyer J, Dozor AJ Relationship between symptoms with exercise and results of exercise bronchoprovocation tests in school-age children. *Am J Respir Crit Care Med* 2020;201: A4680.
94. Pollack Y, Mc Allister E, Dozor AJ, Krishnan S. Ventilatory Non-homogeneity in Children with Sickle Cell Disease. *Am J Respir Crit Care Med* 2020;201: A4674.
95. Krishnan S, Lu MA, McInerney A, Trinh VY, Huang W, Bakshi CS, Dozor AJ, Parton LA. Urinary biomarkers of inflammation and remodeling in children with asthma and resistant airflow obstruction. *Am J Respir Crit Care Med* 2020;201: A4534.
96. Khazaei Nejad S, Brown A, George BA, Dozor AJ. Evolving Pediatric Concerns with EVALI (E-cigarette, or Vaping, Product Use Associated Lung Injury). *Am J Respir Crit Care Med* 2020;201: A2004.
97. Welter JJ, Lennox A, Krishnan S, Kim C, Thompson H, McAllister EE, Krishnan SV, Huang K, Nwaedozie K, Spad M, Dozor AJ. The relationship between obesity and pulmonary function in people with cystic fibrosis. *NACFC 2020: Pediatric Pulmonology* 55, S301-S301.
98. Lindsay-Adler D, Krishnan S, Au K, Messer Z, Dozor AJ. Holness L. Management of Obesity in Children with Asthma Using Nutrition Video Counseling. *Journal of Nutrition Education and Behavior*, Volume 52, Issue 7, Supplement, July 2020, Page S92.
99. Milne, J, Friedman D, D'Souza M., Krishnan S., Klejmont L, Morris E., Mahanti, H, Otero, N., Brudnicki A., Cooke, K. and Cairo, M. Preliminary safety results of defibrotide in SCD patients with acute chest syndrome (IND 127812). *Pediatric Blood & Cancer* June 2020, Vol. 67, pp. S44-S44.

100. Siegel S, Agress A, Avner D, Dozor AJ, Krishnan S. Risk Factors in atopic dermatitis in children (RIFINAD). Pediatric Academic Societies Meeting, Philadelphia, 2020. PAS 2020 Meeting Program Guide.
101. Ferguson KF, Krishnan S, Sullivan E, Dozor AJ, Welter JJ. Identification of environmental tobacco smoke (ETS) exposure and implementation of proven measures to decrease exposure. Pediatric Academic Societies Meeting, Philadelphia, 2020. PAS 2020 Meeting Program Guide.
102. Lindsay-Adler D, Krishnan S, Au K, Messer Z, Dozor AJ. Management of Obesity in Children with Asthma using Telehealth (MOCATEL). Pediatric Academic Societies Meeting, Philadelphia, 2020. PAS 2020 Meeting Program Guide.
103. Pollack Y, McAllister E, Dozor AJ, Krishnan S. Ventilatory Non-homogeneity in Children with Bronchopulmonary Dysplasia. Assistant Professor Symposium, Maria Fareri Children's Hospital and New York Medical College, Valhalla, NY 2020.
104. Ferguson KF, Krishnan S, Sullivan S, Dozor AJ, Welter JJ, Identification of environmental tobacco smoke (ETS) exposure and implementation of proven measures to decrease exposure. Paul Woolf Research Symposium – Maria Fareri Children's Hospital and New York Medical College, Valhalla, NY 2020.
105. Krishnan S, Parton L, Bakshi C, Dozor AJ. Differential gene expression between children with asthma and resistant obstruction versus reversible obstruction using meta-transcriptomic next-generation sequencing. Poster Presentation at American Thoracic Society International Conference May 2021.
106. Krishnan S, Lindsay-Adler D, Au K, Ansehl A, Messer Z, Dozor AJ. Management of obesity in children with asthma using telehealth (MOCATEL). Poster Presentation at American Thoracic Society International Conference May 2021.
107. Siegel S, Agress A, Avner D, Dozor AJ, Krishnan S. Environmental risk factors in children with atopic dermatitis. Poster Presentation at American Thoracic Society International Conference May 2021.
108. Nejad SK, Kim C, Rooney E, Dick-Godfrey R, Krishnan S, Nolan S, Wange G, de la Riva-Velasco, E, Ronau R, Wallace K, Dozor AJ. Childhood asthma after viral lower respiratory tract infection before 3 years of age: A comparison between EV-D68, Non-Ef-D68 EV/RhV, and RSV. Poster Presentation at American Thoracic Society International Conference May 2021.